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Cancer is one of the leading causes of mortality with approximately 14.1 
million new cases and 8.2 million deaths worldwide reported by 
GLOBOCAN Colorectal cancer (CRC) is the third most diagnosed cancer in 
males and second in females worldwide. In the South African population, 
CRC incidence rate was 6.5% and the death rate was 6.4% from total 
number of cancer cases (Cancer country profile, WHO, 2020). Present 
cancer treatments include radiation therapy, surgery and conventional 
chemotherapy which is limited due to nonspecific targeting, poor solubility, 
and rapid drug clearance (Senapati et al., 2018). Major issues with cancer 
cells are metastasis, invasion, and recurrence. After treatment small 
populations of cells actively form tumours within the same organ or nearby 
organs due to the presence of cancer stem cells (CSCs). Cancer stem cells 
are a small subset of neoplastic cells capable of tumourgenesis, they have 
characteristics like normal stem cells (SCs) which include, self-renewal and 
pluripotency through which the generation of heterogeneous cells can 
construct the entire tumour (Lundin et al., 2013).  
In recent years, nanotechnology coupled with photodynamic therapy (PDT) 
has received considerable attention in terms of improving the effectiveness 
of drug delivery in cancer therapeutics. Photodynamic therapy is a principle 
whereby a photosensitizer (PS) absorbs a photon of energy at a specific 
wavelength of light and transfers that energy into singlet oxygen molecules 
(Eun et al., 2016). PDT is a minimal invasive cancer treatment that has 
clinically been approved by the FDA and used to treat various tumours, is 
compatible, low cost, effective and has with minimal side effects (Mukai et 
al., 2016). Chlorin e6 (Ce6), is a naturally derived heterocyclic aromatic PS 
molecule and it is synthesised from chlorophyll-a. Ce6 accumulate in target 
tissue, has a strong absorption wavelength between 650-670 nm and no 
side effects to biological tissue (Juzeniene et al., 2009). 
Single walled carbon nanotubes (SWCNTs) are nanosized hollow 






It has a wide surface area to carry drugs, PSs, and biological substances, 
and, when the SWCNTs are coupled with biological molecules they are 
biocompatible, excellent nanocarriers and non-toxic to normal cells while 
excreted through the urine. The development of functionalised single walled 
carbon nanotubes (SWCNTs) has become revolutionary in targeted PDT 
delivery since it improves the therapeutic index of drugs (Singh et al., 2012).  
Hyaluronic acid (HA) is a biocompatible and well-known biodegradable 
biopolymer which is widely distributed in human epithelial, neural and 
connective tissues (Fallacara et al., 2018). Furthermore, it has a high affinity 
towards CD44 receptors which are overexpressed in various CSCs, 
including colon cancer. Thus, HA can act as a targeting ligand when coupled 
with SWCNTs to favourably target colon cancer stem cells (CCSCs) and aid 
in delivering active molecules such as anticancer PS drugs for PDT 
treatment. 
The aim of this study was to synthesise nanobiocomposites using SWCNTs, 
HA and Ce6. Carboxylated SWCNTs and amine activated HA were 
covalently coupled by carboxyl-amine cross linking. Then the loading of Ce6 
on SWCNTs couple HA was achieved by non-covalent π-π interaction 
techniques. The newly synthesised nanobiocomposite (SWCNTs-HA-Ce6) 
effectively targeted the CD44 receptors in the CCSCs. The physicochemical 
characterisation of synthesised SWCNTs-HA-Ce6 was analysed using 
ultraviolet Visible (UV-Vis) spectrophotometer, Fourier transformation 
infrared spectroscopy (FTIR), particle size and zeta potential analysis using 
DLS method, morphological evaluation by high-resolution transmission 
electron microscope (HR-TEM) and X-ray diffraction (XRD).  
The dispersibility of SWCNTs-HA-Ce6 was significantly improved than 
SWCNTs alone due to the coupling of the biopolymer HA. CCSCs were 
isolated using the magnetic bead antigen antibody technique from Caco-2 
colon cancer cell lines. SWCNTs coupled HA and coated with Ce6 were 
successfully synthesized and the results of physicochemical 






PDT applications. The maximum absorbance peak for Ce6 was measured 
with UV- vis spectrophotometer and it appeared at two different 
wavelengths, 664 nm and 404 nm. The surface chemistry and chemical 
bond shifting of the synthesised SWCNTs-HA-Ce6 were analysed using 
FTIR. Crystallinity and purity of the samples were analysed using XRD- 
write out first time used, and the results were closely corresponding to the 
planes of graphite’s, according to the JCPDS #751621. The particle size 
and surface charge of the synthesised SWCNTs-HA-Ce6 were analysed 
using dynamic laser scattering (DLS) method and it showed approximately 
203 ± 6.6 nm and -18.9±1 mV, respectively. Structural morphology of 
synthesised SWCNTs-HA-Ce6 were analysed using HR-TEM, it showed the 
tubular structure of nanotubes, and the shape was consistently maintained 
without breaking until the final product.  
The stability of the synthesized SWCNTs-HA-Ce6 were tested against both 
physiological pH 7.4 and intracellular pH 5.5 and showed significant stability 
in both conditions. This study revealed enhanced stability of Ce6 on 
SWCNTs-HA. Ce6 loading percentage was achieved at 70% on SWCNTs-
HA and in vitro Ce6 release study showed the slow and sustained release 
of Ce6 at pH 7.4 & 5.5. The results obtained from in vitro release studies 
were fitted with different mathematical equations (zero order model, first 
order model, Higuchi model and Korsmeyer-Peppas model). It indicated that 
the Ce6 release pattern from the SWCNTs-HA-Ce6 followed the Higuchi 
kinetic release and the release mechanism followed the Korsmeyer-Peppas 
equation. The Ce6 release mechanism was followed the Non-Fickian 
transport mechanism and it was controlled by more than one process, it may 
be the coupling of fickian diffusion and polymer matrix relaxation. 
Intracellular localisation of synthesised SWCNTs-HA-Ce6 molecules 
showed more fluorescence intensity in the mitochondrial region of Caco-2 
cells and comparatively very less fluorescence intensity of SWCNTs-HA-
Ce6 in lysosomes and the nuclei region. CCSCs were isolated from Caco-






characterisation of isolated CCSCs indicated spheroid formation. It was 
further confirmed by both flow cytometry analysis and immunofluorescence.  
The effect of PDT on isolated CCSCs were studied at 660 nm laser 
irradiation with two different laser fluences of 5 and 10 J/cm2 at 24 and 48 
h. In 10 J/cm2, the cytotoxicity results of SWCNTs-HA-Ce6 on CCSCs 
showed 86.7% at 48 h and 74.8 % at 24 h of incubation. The metabolic 
activity of the isolated CCSCs was tested before and after treatment by 
evaluating the ATP luminescence signal produced by viable cells. When the 
metabolic rate or ATP production in cells are low, it leads to inactivity and 
pronounced cell death. The results of 0, 5 and 10 J/cm2 laser fluences were 
compared and 10 J/cm2 showed more promising outcomes after 24 and 48 
h. ROS production of CCSCs after laser irradiation were analysed and the 
fluorescence intensity of Cy5 showed its highest peak at 10 J/cm2 compared 
to 5 J/cm2. The stages of cell apoptosis were analysed using FITC Annexin 
V and PI stain using 0, 5 and 10 J/cm2 at 24 and 48 h. There were less 
apoptotic cells seen in 0 and 5 J/cm2, whereas 10 J/cm2 showed an 
increased range of early and late apoptotic counts. The study suggested 
that there was prominent cell death using 10 J/cm2 compared to both 0 and 
5 J/cm2.  
Therefore, the combined effect of PDT and SWCNTs-HA-Ce6 showed 
increased cytotoxic and cell apoptosis at a laser fluence of 10 J/cm2 at 48 
h. In conclusion, the combined effect of photodynamic therapy and 
synthesised Ce6 loaded SWCNTs-HA-Ce6 on CCSCs are effective 
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CHAPTER 1                                 INTRODUCTION 
 
1.1. Background 
Cancer is a major burden on global health and in South Africa. Worldwide large 
populations are affected, and mortality rate is high, lack of excise, food habits, 
obesity, Ultraviolet (UV) radiation, genetic disorder are the main causes of cancer 
(Anand et al., 2008). Colorectal cancer (CRC) is the third most common cancer 
diagnosed in men and women, and if the CRC metastasizes to other parts of the 
body, the patient’s 5-year survival rate is 15% (Rebecca et al., 2019).  
Photodynamic therapy (PDT) is a relatively innovative and emerging technique 
to treating cancer, which involves three sources: light source such as laser (Light 
amplification by stimulated emission of radiation), photosensitizers (PS) and 
reactive oxygen species (ROS). When the PS molecule is subjected to target 
cells and then irradiated at a specific wavelength, it stimulates the production and 
activation of a singlet oxygen that leads to cell necrosis or apoptosis (Moan et al., 
2003). PDT successfully treats various medical field such as dermatology, 
urology, gynaecology and oncology (Kharkwal et al., 2011; Sperandio et al., 
2013; Luo et al., 2017). 
Stem cells (SCs) are referred to as pluripotent, multipotent or unipotent, self-
renewing cells, and are broadly classified into two types: embryonic stem cells 
and adult stem cells based on their characteristics and origin (Orlic et al., 2002). 
Cancer stem cells (CSCs) are characterised by self-renewal and asymmetrical 
division properties and the ability to form tumour cells with different phenotypes 
(Adams et al., 2008). CSCs were present in most types of cancer, including CRC, 
breast, brain, melanoma, leukemia and liver cancer (Phi et al., 2018; Batlle et al., 
2017). 
Nanotechnology deals with nanosized particles for innovative applications in a 
different field, nanomedicine is one of the applications specifically involved in 
drug delivery, targeting, diagnostics, imaging and regenerative medicine (Alexiou 
et al., 2015). Carbon nanotubes (CNTs) are nanosized hollow cylindrical 
structured tubes, classified into three types: single walled carbon nanotubes 






nanotubes (MWCNTs). SWCNTs are monolayered graphite sheet rolled into the 
tubular structure between 0.2-3 nm in diameter, wide application in the fields such 
as biomedical, nanocarrier, imaging (Baughman et al., 2002). Pristine CNTs are 
generally toxic to the normal cells, and it often need surface modification with 
biological compounds. The biodistribution of CNTs are excellent when coupled 
with long polymers or biological substances. SWCNTs are the best nanocarriers 
in terms of high surface area, biological distribution, biocompatibility, and enter 
in and out activity on the cells (Ali-Boucetta et al., 2013).  
1.2. Problem Statement 
In South Africa, CRC is the second most common cancer in men and third most 
common cancer in women, according to the reports published by cancer 
association of South Africa (CANSA, 2019). Currently available cancer 
treatments are chemotherapy, radiotherapy, monoclonal antibodies 
immunotherapy and surgery, while present therapies have severe side effects 
such as killing healthy cells, non-specificity and poor bioavailability. Scientists are 
optimistic about the potential of nanomaterials to increase the bioavailability of 
the drug by targeting cancer cells (Badea et al., 2020).  
Cancer stem cells are small populations of cells that resist chemotherapy and 
then regenerate into tumours, leading to the failure of cancer treatment (Mansoori 
et al., 2017). Recent studies have shown that a group of cells that begin initiating 
the tumour occurrence and recurrence after treatment commonly referred to as 
cancer stem cells. Researchers are now focusing on targeting the heart of cancer 
named as CSCs, which will completely eradicate the tumour from the affected 
organs.  
In the nanobiocomposite synthesis for drug delivery system, the main issues are 
solubility (hydrophobic and hydrophilic nature of the nanoparticles), dispersion of 
particles, cell targeting, engulfment of cells, drug release in target cells, stability 
of the nanobiocomposite. The size of the nanoparticles also plays an important 
role in transporting the drug to cancer cells (Patra et al., 2018). 
Nanobiocomposite should be designed and integrated to target the CSCs based 






The combination of photodynamic therapy and nanomedicine is a novel emerging 
treatment that target and kills the CSCs to destroy cancer from affected organs. 
The novel application of PDT and SWCNTs nanobiocomposite to eradicate 
CCSCs for the treatment of colon cancer. This approach will significantly reduce 
the side effects, recurrences, metastatic effect and reduce the cancer death rate.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
1.3. Specific Aim  
Isolation of CCSCs from Caco-2 colon cancer cell lines using surface markers 
CD 44, CD133 and CD24. Isolated cells were cultured in ultra-low attachment 
flasks to maintain the stemness for further studies. In order to evaluate the effects 
of PDT and nanobiocomposite (SWCNTs functionalised HA and loaded 
photosensitizers Ce6) on CCSCs, the synthesised nanobiocomposite were 
incorporated into the isolated CCSCs and treated with PDT at 660 nm. 
The following objectives were achieved:  
 Synthesised HA functionalized SWCNTs loaded with chlorin e6. 
 The physicochemical characterisation of the newly synthesised 
nanobiocomposite analysed using UV spectrophotometer, Fourier 
transmission electron microscope (FTIR), X-ray diffraction (XRD), particle 
size analysis and zeta potential (DLS method), High resolution-
transmission electron microscope (HR-TEM). 
 The photosensitizer stability analysis using different pH conditions. 
 In vitro photosensitizer release study using dialysis technique. 
 Isolation of Caco-2 CCSCs using CD133, CD44, CD24 markers by 
magnetic bead method. 
 Characterisation of isolated CCSCs using immunofluorescence 
microscopy technique and flow cytometry analysis. 
 The anticancer activity of the newly synthesised nanobiocomposite under 
PDT treatment on CCSCs. 
 The Nuclear damage of the CCSCs under PDT treatment analysed using 
Hoechst/propidium iodide staining. 
 The oxidative stress of the CCSCs under PDT treatment analysed using 
reactive oxygen species (ROS) analysis using intracellular ROS assay 


































CHAPTER 2                           LITERATURE REVIEW 
2.1. Cancer 
The term cancer refers to a deadly disease in the present era. Globally, the 
burden of cancer affects every individual family due to physical, emotional and 
financial crisis. Cancer, a group of mutated cells in an uncontrollable growth 
condition, forms a tumour at a specific site and spreads throughout the body. The 
metastasizing process is the leading cause of death for cancer. Other names for 
cancer include malignant tumour, neoplasm, lymphoma etc (Lopez-Lazaro et al., 
2016; Martin et al., 2013). Worldwide, cancer is the second leading cause of 
death, around 9.6 million deaths or one in six deaths in 2018, according to a WHO 
report (WHO, 2018).  
Cancer is caused by genetical disorder, physical inactivation, poor diet, smoking, 
alcohol & tobacco consumption, obesity, ultraviolet (UV) rays, constipation, 
stress in modern habits and certain infections also causing cancer like Human 
papillomavirus (HPV), Epstein-Barr virus, Hepatitis B and C viruses (Bray et al., 
2018). The physical, chemical and biological cause of cancer are explained in 
Figure 2.1. 
 







Metastasis, invasion and recurrence are the major issue in the cancer treatment, 
in the process of metastasis, the malignant phenotype must be obtained to 
separate the tumour cell from the primary tissue and passes through the 
extracellular matrix, basal membrane and intravasate into circulation of the body 
(Spano et al., 2012). Some examples of metastatic sites for specific cancers are 
listed in Table 2.1. Cancer invasion involves in migration of cancer cells through 
the cellular matrix and spreads into neighbouring tissues. After treatment or 
removal of tumour, few subpopulation cells survive and reach metastasis and 
invasion (Darvishi et al., 2020). 
 
Table 2. 1 Few lists of primary tumour and metastatic sites in the body (Martin et 
al., 2013). 
 
Primary tumour Metastatic sites 
Colorectal cancer Liver and lung 
Lung cancer Brain, bone, adrenal gland and liver 
Breast cancer Bone, lungs, liver and brain 
Prostate cancer Bone 
Skin melanoma Lung, brain, skin and liver 
 
Local recurrence after surgical resection is a foremost complication in the 
treatment of cancer, and it plays major role in decreased survival and quality of 
life for patients. Drug resistance cancer cells can quickly form tumours in distant 
organs. Most researchers find that recurrence of cancer due to the cancer stem-
like cells are resistant to all treatments (Hiller et al., 2018; Meyerhardt et al., 
2006).The term cancer is a main challenge for clinicians and researchers who 
interested in the field of diagnosis and treatment. 
In the current scenario many unknown types of cancer are growing in the human 
body, researchers and doctors are naming the cancer based on the type of cell, 






types of cancer are listed in Figure 2.2. The most common types of cancer in men 
are lung, prostate, colorectal, liver & stomach and the most common types of 
cancer in women are breast, colorectal, lung, thyroid and cervical cancer (Bray 
et al., 2018).  
 
 
Figure 2. 2 Different types of cancer. 
 
2.1.1. Colorectal cancer 
Colorectal cancer (CRC) is also known as bowel cancer or colon cancer or rectal 
cancer. Colon cancer treatment leads to failures due to the metastasis and 
invasion (Zheng et al., 2014).  The main cause for the CRC accretion of genetic 
and epigenetic alterations, it forms additional layer of complexity to induce CRC 
(Valastyan et al., 2011). The polyp (abnormal or noncancerous growth of tissue) 






eventually  forms a tumour in a region referred to as CRC and later stage it has 
capable of spreading and growing to the nearby organs through lymph and blood 
stream. CRC is very difficult to diagnose in the early stages of tumour (Marley et 
al., 2016). The structure of colon and tumour in the colon region is illustrated in 
the Figure 2.3. 
 
Figure 2. 3 Structure of colon and tumour present on the walls of colon. 
 
In modern culture, changes in their daily habits can lead to the risk of CRC such 
as poor diet (Boyle et al., 2000) (high fat consumption and low fibres), lack of 
exercise, tobacco usage, alcohol consumption (Bishehsari et al., 2014), age 
factor (Raycraft et al., 2019), obesity (Ding et al., 2020), Crohn’s disease and 
ulcerative colitis in colon (Pacal et al., 2020). Common symptoms of CRC 
constipation, changes in stool colour & shape (narrowed stool), diarrhoea, blood 
in the stool, abdominal cramps and pain, fatigue, vomiting and appetite loss 






Based on the tumour region CRCs are classified as carcinoid tumours (cancer 
cells grow in the hormone producing intestinal cell region), gastrointestinal 
tumour (tumours in the cajal region), sarcomas (colorectal walls and stromal 
region) (Chelliah et al., 2019). The four stages of CRC listed in the table 2.2. 






Stage 0 Carcinoma in-
situ 
Abnormal cells are 
located on the inner lining 
of colon or rectum 
No symptom 
Stage 1 Carcinoma 
penetration 
Cancer cells penetrate the 
lining or mucous into the 




abdominal pain   
Stage 2 Early stage Cancer cells spreads to 
nearby tissues through 
the walls of colon or 
rectum  
Blood in rectum or 
stool, abdominal 
cramps 
Stage 3 Late stage Cancer cells moved to 





Stage 4 Late stage Cancer cells moved to 
distant organs liver and 
lungs. 
Jaundice, swelling 
of hands and legs, 









2.1.2. Statistics report of colon cancer in South Africa 
South Africa is a modern and westernized cultured country and CRC ranks in the 
top five on the list of most diagnosed cancers (Bray et al., 2012; The World bank 
2016). CRC is a second most common cancer among men and fourth most 
common cancer among women in South Africa (CANSA, 2010). Total population 
of South Africa around 57.78 million in the year 2018 and total cancer cases in 
the year 2018 was 107,467 cases, then death cases in 2018 was 57,373. The 
rate of CRC incidence was 6.5 % and the mortality was 6.4% from total number 
of cancer cases (WHO, 2020). Figure 2.4 shows the percentage of males and 
females affected by colon cancer in South Africa. The total population of South 
Africa was covered by four different races, and the percentage of colon cancer 
among them is given in Figure 2.5. 
 







Figure 2. 5 Pie chart for percentage of people population affected by colon cancer 
in South Africa. 
 
2.1.3. Present cancer treatments 
To treat cancer patients, there are currently two ways of treatments available 
local and systematic treatments, which are mentioned in Figure 2.6. Local 
treatment such as surgery and radiation therapy involve treating the tumour 
without affecting any other parts of the body. Systematic treatment involves 
chemotherapy, immunotherapy, gene therapy using a drug that is administered 
orally or directly into the bloodstream and it reaches all over body and destroying 







Figure 2. 6 Schematic diagram of cancer treatments. 
 
CRC treatment involves laparoscopic surgery, colostomy for rectal cancer, 
radiofrequency ablation (RFA) or cryoablation if the tumour size was small or has 
reached metastatic stage. Chemotherapy and radiation therapy also using for 
CRC but have many side effects (Seligmann et al., 2020).  
2.2. Stem Cells  
2.2.1. Characteristics and types of stem cells 
Stem cells are a group of cells must have the ability to differentiate and unlimited 
self-renewal to produce progeny exactly similar like parent cell. SCs plays an 
important role in every stages of body growth from embryo formation, pluripotent 
represents progenitors for development of tissues, SCs differentiate and develop 
every organs of the body. SCs are mainly characterised as self-renewal, 
differentiation, quiescence, migration, recreation of functional tissues (NIH, Stem 
cells 2008).  
SCs can differentiate in two ways and it based on the different cell type and 
biological properties. Essentially, SCs describe cell development as “embryonic” 






Recently, researchers discovered how to turn differentiated adult cells into 
embryonic stem cells. The adult SCs are also known as somatic SCs found in 
the placenta, fetus, and umbilical cord (Bajada et al, 2008). 
SCs are classified into two types based on their biological properties: pluripotent 
and multipotent SCs. Pluripotent SCs are capable of differentiating in all types of 
cells which are present only very short time in the embryo before differentiation. 
Multipotent SCs are specialized cells of the tissues in the body, the cells of germ 
line, that multiply themselves into restricted specialized cells (Molfsky et al., 
2004). The derivation of SCs are explained in the Figure 2.7. 
 








2.2.2. Cancer stem cells 
2.2.2.1. Theories of cancer stem cells 
In recent years, cancer therapies have faced a serious failure due to the 
recurrence of the tumour. The researchers found that a group of cells resisted 
chemo drugs and regenerated the tumour rapidly, with these cells having the 
properties of stem cells with the ability of forming tumours called cancer stem 
cells. The first CSCs were identified in solid tumours of human breast cancer. 
The small population of human breast cancer cells were administered in immune-
compromised mice for tumour formation. CSCs have been positively identified in 
and isolated from various human solid tumours including colon, pancreatic, head 
& neck, cervical and brain cancer. 
 
CSCs similar to normal SCs homogenous and heterogenous division concept. 
CSCs can divide both symmetrically producing two daughter CSCs and 
asymmetrically producing different daughter cells (Santoro et al., 2016). Three 
important criteria of CSCs in solid tumours are:  
 
i. Not all the cancer cells CSCs, only small population of cancer cells have 
the ability to form tumours. 
ii. The small population cells are identified by cell surface markers such as 
CD 133, CD 24, CD44, CD 90, Myc, KLF 4, ALDH, EPCAM etc. 
iii. CSCs can form secondary tumour with full phenotypic heterogeneity of the 
primary tumour. 
 
2.2.2.2. Cancer stem cell markers and pathways 
In different types of cancer, cell surface markers will vary, and CSCs are identified 
based on markers. These cell surface markers are membrane proteins, specific 
to particular antibodies that helps to differentiate CSCs and non-CSCs 






















liver, lung, ovary 
(Grosse-Gehling 
et al., 2013; 
Irollo et al., 
2013; Yin et al., 
1997; Sundberg 
et al, 2009) 




(Li et al., 2007; 
Ng et al., 2010; 
Patriarca et al., 
2012) 
3 CD24 B cell proliferation Breast, gastric, 
Pancreas 
(Al-Hajj et al., 
2003; Zhang et 
al, 2011) 






(Thapa et al., 
2016; Lapidot et 
al., 2005; Zuk et 
al., 2002; Zoller 
et al., 2011) 
5 CD49f Cell adhesion Glioma (Yu et al., 2012; 
Lathia et al., 
2010)  
6 SSEA 3 
 
hESC marker Teratocarcinoma, 
Breast 
(Thomson et al., 
1998; Kuroda at 
al., 2010)  
7 CD96 T cell-specific 
receptor 











The isolation and characterisation of CSCs depend on the cell surface antigen of 
respective cancer cells. Confirmation of CSCs by surface antigens is linked with 
their operational characteristics because of factors influencing their expression 
(Tirino et al., 2013). 
 
Isolated small population of CSCs are clearly identify using low Hoechst 33342 
dye staining, this stain eluding the dye by ATP-binding cassette (ABC) (Ozvegy-
Laczka et al., 2005). ABC are transmembrane proteins that binds to adenosine 
triphosphate and hydrolyses, these proteins that acts as receptors and multidrug 
transporters that use ATP to discharge cell endogenous molecules and cytotoxic 
agents. Due to these mechanism CSCs are multidrug resistance and leads to 
failure of cancer treatment (Bleau et al., 2009). CSCs are also resistance to 
chemotherapy due to the enzyme aldehyde dehydrogenase oxidizing aldehydes, 
which converts retinol into retinoic acid (Russo et al., 1998). 
CSCs are aggressive and uncontrolled cell division in tumour, pathway 
dysregulation of SCs leads to CSCs. Cell cycle and arrest mechanism are 
regulated by Wnt-β-catenin in SCs and self-renewal of SCs regulated by Notch 
pathway (Gedaly et al., 2014; Chiang et al., 2013). The Hedgehog signalling 
pathway was named after the origin of the polypeptide ligand and intercellular 
signalling molecule.  
 
Importantly, three homologues have been identified in Hedgehog pathway, they 
are human’s Hedgehog, desert Hedgehog, Indian Hedgehog and the most widely 
studied Sonic hedgehog (Rubin et al., 2006). The Sonic Hedgehog pathway 
involves in the activation of SCs to create different SC models, but in CSCs the 
signalling process of self-renewing genetic programs are activated by this 
mechanism (Visvader at al., 2012; Zhang et al., 2015). CSCs are resistance to 
all therapy due to activation of several signalling pathways, such as Notch, Wnt/β-
catenin, TGF-β, Hh, RAS, PI3K/Akt/mTOR and JAK/STAT pathways (Islam et 
al.,2015). Mainly in colon cancer or bowel diseases, the inflammation in colon 
might be activated by Notch or Hedgehog signalling further expands to colon 







2.2.3. Colon cancer stem cells 
The colon cancer stem cells (CCSCs) are derived from malignant transformation 
of normal tissue stem cells present in colon region or from dedifferentiation of 
matured cells (Friedmann- Morvinski et al., 2014). Recent studies suggest the 
existences of CCSCs or colon cancer initiating cells isolated from known colon 
cancer tumours. In human breast cancer, stem cells are isolated and identified 
using cell surface antigens in flow cytometry. This is corresponding to the 
tumorigenic phenotype of stem cells (Rubin et al., 2006).  
 
In CCSCs are mainly identified on the basis of cell surface antigens. O’Brien et 
al., (2007) isolated CCSCs using CD133 markers from seven different primary 
colon cancers and ten different extracolonic or metastatic sites. The isolated 
tumorigenic cells were then injected into nonobese diabetic/severe combined 
immunodeficiency (NOD/SCID) mice. CD133+ cells are analysed on both tumour 
region and normal cells area. The tumour region ranged about 3.2-24.5% of 
CD133+ in tumour cells and the normal cells ranged about 0.4-2.1% (O’Brien et 
al., 2007). 
 
To prove the pluripotent potential of CCSCs in their subpopulation, CD133 
markers are used to identify and isolate the tumorigenic cells from colon cancer. 
These isolated cells were immortalized in vitro as floating colonies or tumour 
spheres and maintained in several passages. Then the CD133+ spheres mixed 
with CD133+ and CD133 populations, but only the CD133+ cells are tumorigenic 
(Ricci-Vitiani et al., 2007). 
 
In CCSCs, the most familiar and cell surface marker was CD44 which plays role 
in cell and cell matrix interaction through its hyaluronic acid, involves in cell-
adhesion and assemble the growth factors on the cell surface (Marhaba et al., 
2004). CD44 variants isoforms roles are not completely understood, even though 
some are mediated in colon cancer metastasis (Du et al., 2008; Banky et al., 
2012). CD44 receptor immunoprecipitated with ErbB tyrosine kinases family 






Downstream signalling of CSCs via phosphor-inositol 3 kinase (PI3K)/AKT 
pathway mainly regulated by EGFR (Ma et al., 2013). 
 
In 50-68% of tumour cells in CRC patients expressed CD24 antigens, and CD24 
is a cell surface protein that is expressed in the outer region of the plasma 
membrane. The CD24 marker has some specific role in the immune system and 
central nervous system (Weichert et al., 2005; Choi et al., 2010). In the colon 
cancer, the CD24 positive side populations possess stemness or stem cell like 
properties (Ke et al., 2012). In this study, the isolation and characterisation of 
CCSCs is based on three markers CD133, CD44 and CD24. 
 
2.3. Photodynamic Therapy 
2.3.1. History of phototherapy 
In ancient times, sunlight was used as a source to treat different diseases in many 
countries such as China, India and Egypt. From the 15th to the mid-19th century, 
people were treated for skin ailments following sun therapy, called heliotherapy. 
After the introduction of modern medicine people started forgetting about sun 
treatment (Grzybowski et al., 2016). In china, ancient medicine based on different 
colours for each disease and then sunlight for men and moonlight for women’s 
(Needham et al., 1983). Indian way of treatment based on to apply the plant 
extract or oil (seed oil or ayurvedic oil) on the affected area and exposure to 
sunlight (Pathak et al., 1992). Modern phototherapy was looming in the field of 
biomedical to treat different diseases.  
 
The first ultraviolet therapy was used to treat Lupus vulgaris by chemical ray’s 
lamp, succeeded by Niels Ryberg Finsen who was named as father of ultraviolet 
therapy (Honisgsmann et al., 2013). In 19th Century slowly the treatment evolved 
into ultra vitalux lamp, fluorescent tubes (Wiskemann et al., 1963) and 
photochemotherapy psoralen and Ultraviolet A (PUVA) (Wolff et al., 1976). 
During 1980’s, extra corporeal photochemotherapy (extracorporeal 
photopheresis, ECP) was termed as phototherapy, this technique was introduced 
to treat palliative of erythrodermic cutaneous T-cell lymphoma approved by FDA 









Figure 2. 8 Mechanism action of phototherapy. Photosensitizers, PBM- Photo 
biomodulation mechanism of light source on cells leads to cell proliferation. PDT- 
Photodynamic therapy mechanism of incorporation of PS into the cells with light 
source emission leading to PS molecule activation induces singlet oxygen 
production and cell death. PTT- Photothermal therapy mechanism of addition of 
nanomaterials, which has thermal property after the introduction of light source, 
produces heat energy leading to cell death. (Sundaram et al., 2020b). 
 
Thus, phototherapy attracted research scientists and discovered enormous 
therapeutic techniques for various diseases. The phototherapy was mainly 
classified as photo biomodulation (PBM): the low-level light source at a particular 
wavelength applied into the cells it will stimulate or enhances the cells (Asgari et 
al., 2020), photodynamic therapy (PDT): the PS molecule in the ground state, 
when the molecule activated by light source reaches excited state and convert to 
triplet state by electron spinning. The triplet state interacts with surrounding 






al., 2016), and photothermal therapy (PTT): The particle (PS or nanoparticles) 
will be activated by the light source and produce thermal energy to destroy cells 
(Junqi et al., 2019). The mechanism action of phototherapy was shown in Figure 
2.8. 
 
2.3.2. Overview and Mechanism of photodynamic therapy 
Photodynamic therapy is an emerging medical treatment and in-depth research 
is underway during this period to introduce new treatments for deadly diseases. 
This treatment deals with three major components light source, photosensitizers 
and singlet oxygen. When the light source emits at a specific wavelength to 
activate the PS molecule and it produce singlet oxygen in the cell then it leads to 
cell death, specifically cancer cells (Dolmans et al., 2003; Hopper et al., 2000). 
 
Figure 2. 9 Mechanism action of photosensitizers (PS), activation of PS molecule 
and its Type I and Type II reactions on cell. 
 
In 1978, Thomas Dougherty and co-workers first and successfully tested PDT in 
clinical test to treat cancer in preclinical models at Rosewell park cancer institute 
(Patrice et al., 2003). PDT has more therapeutic efficacy and improving outcomes 
for cancer treatment in comparison to commercially available chemo and 
radiotherapy (Detty et al., 2004). The mechanism action of PDT involves two 
main types, both are based on production of oxygen molecules inside the cells 







Type I mechanism of PDT: The activated PS molecule in the excited triplet state 
can transfer energy from its surroundings to the biomolecules. The excited triplet 
PS molecule and the substrate tissue, an electron or hydrogen is transferred, 
which leads to the formation of free radicals and anions. These electrons interact 
with the oxygen molecule to produce reactive oxygen species (ROS) (Nowak-
Stepniowska et al., 2013; Luksiene et al., 2003).  
 
Type II mechanism of PDT: The activated PS molecule in the excited triplet state 
can transfer energy directly to the oxygen molecule (PS to O2) it is possible to 
transfer because they have the same spins. Based on the ROS production level 
cause photodamage of proteins (Kessel et al., 2010), cell membrane destructions 
(Plaetzer et al., 2003), damage of fats and other molecules, damage of 
lysosomes or endoplasmic reticulum provoke autophagy in the targeted area or 
leads to the tumours cells apoptosis (Buytaert et al., 2007). 
 
2.3.3. Role of photosensitizers in PDT 
Photosensitizers are naturally derived or chemically formed compounds, that are 
highly sensitive to light source. These compounds are widely used in PDT, at 
specific wavelength PS molecules activated and reaches excited state and 
electron transfers to produce ROS leads to cytotoxicity (Allison et al., 2004). The 
minimum absorption wavelength range between 400-600 nm prevents excessive 
sensitivity from sunlight, 600-800 nm are the maximum absorption wavelength, 
above 800 nm will not provide excess oxygen production (Agostinis et al., 2011; 
Kou et al., 2017). 
 
PS molecules are actively used in cancer therapy, often the PS molecules are 
derived from the tetrapyrrole compounds, which resembles haemoglobin due to 
the presence of protoporphyrin prosthetic group which can easily penetrate into 
cells (Abrahamse et al., 2016). PS compounds differs into three categories based 
on evolution such as first, second and third generation. In 1904, Oscar Raab 
explained to his professor Von Tappeiner that acridine dyes are killing protozoa 
under radiation (Allison et al., 2010). In 1970’s commercially available PS 







In 1980’s, second generation PS molecules based on the hematoporphyrin 
derivatives and synthetic PS, were used in clinical trials for anticancer activity 
(Yoon et al., 2013). These generation molecules penetrate deep into the tissues 
and produce more oxygen molecules; they are activated between 650-800 nm 
(Nowak-Stepniowska et al., 2013). Third generation PS molecules are derived 
and synthesised to treat cancer cells, they have high affinity to the tumour cells, 
will not affect the normal cells during PDT. Most of the molecules are metal based 
compounds (Kataoka et al., 2013). Some examples of porphyrinoids PS 




Figure 2. 10 Examples of Porphyrinoids photosensitizers: Porphyrin, Chlorin, 
Porphycene, Bacteriochlorin, Phthalocyanine, Texaphyrin. (Sundaram et al., 
2020b). 
2.3.3.1. Chlorin e6 
Chlorin e6 also known as phytochlorin is a naturally derived chlorophyll-a 






PS for PDT, the main advantage of Ce6 are low toxicity, easy synthesis and 
production, fast and selective accumulation in target tissue, strong absorption 
wavelength between 650-670nm, high singlet oxygen quantum yield, and almost 
no side effects to skin (Juzeniene et al., 2009). The molecular formula and weight 
of the Ce6 are given in Table 2.4. 
Chlorin e6 coupled with nanoparticles or any chemical compounds, there is no 
change in the chromophore, and it has significant photostability. Ce6 decorated 
with doxorubicin and encapsulated with chitosan tripolyphosphate nanoparticles 
to treat breast cancer cells near infra-red ranges. When PS molecules coupled 
with nanoparticles are aimed to improve their photo-controlled stability and 
photoactivity during cancer treatment (Anindita et al., 2019). In drug delivery 
systems, Ce6 molecules coupled with polymers improves the biocompatibility 
and bioavailability of Ce6 (Penelllche et al., 2019). 
 
Table 2. 4 Molecular formula, weight and IUPAC name of Ce6 (Pubchem). 
Name Chlorin e6 
Molecular formula C34 H36 N4 O6 









2.4. Nanomedicine in Cancer 
2.4.1. Introduction of nanomedicine 
Nanomedicine is one of the applications of nanotechnology, mainly involves in 
diagnosis, imaging, therapeutics and regenerative medicine. Newly synthesised 
or chemically available nanosized particles are used in the medical fields. Over 






nanomedicine to treat cancer, diagnosis or imaging process (Fadeel et al., 2020; 
Alexiou et al., 2015). The applications of nanomedicine are listed in table 2.5. 
 
Table 2. 5 Applications of nanomedicine. 
S. No Applications 
1. Nanoparticles in nanomedicine to target 
2. Nano valves for drug delivery 
3. Imaging 
4. Diagnosis  
5. DNA analysis 
6. Gene therapy 
7. Delivery system 
8. Cleaning robots 
9. Implant materials 
10. Wound healing bandages 
11. Body surveillance 
12. Artificial tissue and organs 
 
 
Nanosized particles can be in the range of 1-100 nm, with polymers, dendrimers, 
liposomes, fullerene, silver and gold nanoparticles, metal based-nanoparticles, 
carbon nanotubes, graphene, micelles, quantum dots, silica, hydrogel etc. In 
clinical practice, the benefits of a nanoparticle-based drug delivery system, in 
comparison with commercially available drugs, include protecting from drug 
solubility and inactivation of drug or biodegradation(Bernabeu et al., 2017), 
prolonged circulation without rapidly clearing from body (Gabizon et al., 1994), 
targeting the specific site increases the concentration of drug to kill the 
tumours(Gabizon et al., 2003), possible to load multiple drug for synergistic 
effects on targeted area(Lancet et al., 2016), sustained and controlled release of 
drugs (Dou et al.,2017), enhancing therapeutic efficacy(Lyon et al., 2018). 
Currently available and approved nanomedicines are listed in table 2.6. 
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EMA 2018 Oasmia 
pharmaceutica
l 
(Borga et al., 
2019) 
                      *FDA-Food and drug administration   *EMA-The European medicines agency  
Very few drugs in nanomedicine research have been approved by the FDA and 
EMA, and some cancer nanomedicines have undergone stage 2 and 3 clinical 
trials (Mukai et al., 2016). Recently, researchers are focusing on carbon 
nanoparticles such as carbon nanotubes, graphene oxide, and fullerenes as drug 







2.4.2. Single walled carbon nanotubes  
Carbon nanotubes are nanosized cylindrical tubes that are rolled up by graphene 
sheets where both ends are opened, and carbon atoms are exclusively arranged 
like a benzene ring. The structural representation of the CNTs are armchair, 
zigzag and chiral, with allotropic forms were both sp² planar and sp³ cubic (Mehra 
et al., 2016). Based on the graphene sheets CNTs are classified as single walled 
carbon nanotubes (SWCNTs) sized between 1-3 nm in diameter and several 
micrometres in length. Double layered graphene sheets are rolled to form a 
nanotube named as double walled carbon nanotubes (DWCNTs). Multiple sheets 
that rolled up and formed a tube was named as multi walled carbon nanotube 
(MWCNT) sized between 1-3 nm inner diameter 2-100 nm outer diameter and a 
length ranging from 0.2 to several micrometres (Singh et al., 2012).  
 
The synthesis method of CNTs includes the discharge method, chemical vapor 
deposition (CVD), and laser ablation techniques. Very few natural syntheses of 
CNTs techniques are available but there is no proper yield or standardized 
method (He et al., 2013) The purity of the CNT is achieved by the acid reflux 
method, air oxidation, and surfactant-based sonication to remove the extra 
metals. Purity is considered as an important criterion when it comes to biological 
applications (Donaldson et al., 2006).  
 
Carbon nanotubes play a unique role as nanocarriers to deliver drugs, polymers, 
photosensitizers, and specific ligands to target siRNA and DNA. In cancer 
therapy, conventional treatment such as surgery, chemotherapy or radiotherapy 
has numerous side effects and does not completely get rid of the disease, due to 
poor targeting, bioavailability, and damaging organs (Hou et al., 2002). Many 
scientists are focusing on the CNTs combined biological delivery such as 
polymers, drugs, DNA, PS to target cancer cells (Lei et al., 2014). 
 
SWCNTs have unique size & shape, large surface area and physicochemical 
properties that improve their quality as nanocarriers (Sajid et al., 2016). When 






MWCNTs enter via the endocytosis pathway (Mu et al., 2009). SWCNTs are act 
as a leading nanocarrier for loading different types of polymers, drugs, and photo 
drugs (Marangon et al., 2016). SWCNTs facilitates both covalent and non-
covalent functionalization of targeting moieties that make them unique nano 
carriers in drug delivery systems (Tuncel et al., 2011). The carboxylated SWCNT 
shows excellent biocompatibility in cancer therapy (Tan et al., 2014).  
 
2.4.3. Hyaluronic acid 
Hyaluronic acid is a well-known natural polymer, also known as 
glycosaminoglycans belongs to a heteropolysaccharides group. HA is found in 
human bodies around the joints, umbilical cord, skin and connective tissues 
(Fallacara et al., 2018). HA also produced through microbial fermentation based 
on the oligosaccharides and molecular weight separated as commercial product 
(Tavianatou et al., 2019). HA molecule shows increased stability at physiological 
pH, which is a good quality to act as nanocarrier in drug delivery systems 
(Kobayashi et al., 1994). 
 
The HA molecule widely exists in the extracellular matrix and primarily cleared 
by the lymphatic system (Choi et al., 2010). It has excellent properties of water 
solubility, biocompatibility, it is a biodegradable molecule, has high tumour 
targeting capacity and non-immune toxicity (Liu et al., 2011; Toole et al., 2002). 
Hyaluronic acid specifically recognized for its CD44 receptor and has been 
identified as a potent targeting ligand for tumours over expressing CD44, the 
CD44-HA interaction provides a new approach to targeted diagnosis and 
treatment of specific cancers (Virginia et al., 2008).  
 
Hyaluronic acid functionalized SWCNTs coupled to gadolinium is a promising 
compound for high-resolution magnetic resonance and molecular imaging of 
tumours (Hou et al., 2015). Hyaluronic acid functionalized SWCNTs coupled with 
Salinomycin successfully targeted the CD44 receptors on a gastric cancer cell 
line. The nanocomposite material proved to have a greater cytotoxic effect than 
the drug alone on cancerous cells as well as avoided side effects seen when 







Chemical modifications in HA nanoparticles leads to the possibility of ligand 
modification and poor biocompatibility (Zhang et al., 2014). Many studies have 
been reported that HA-based nanoparticles can be used as an effective 
nanocarrier in tumour accumulation or ablation by phototherapy (Kim et al., 2013; 
Choi et al., 2010).  
 
To identify gastric CSCs, CD44 cell surface markers are targeted using HA, 
because the samples collected from gastric cancer patients, CSCs are isolated 
and tested that CD44 receptors are high. The patients isolated cells possess 
stem cell-like properties such as invasive, spheroid formation in vitro condition, 
drug resistance capacity, migration and tumour formation (Sun et al., 2013; 
Zhang et al., 2011a).  Scientific reports further indicate that CD 44 expression in 
some carcinomas may act as a prognostic indicator for tumour progression, 
metastasis and patient survive (Ghaffarzadehgan et al., 2008; Yoo et al., 1999). 
The complete eradication of the tumour from the body is to target the CSCs and 
to destroy the cells using specific markers of CSCs (Kusunoki et al., 2013). 
 
2.4.4. Mechanism of loading and coupling of biological compounds on 
single walled carbon nanotubes. 
2.4.4.1. Physical loading mechanism 
In the drug delivery system, physical loading mechanism involves the surface 
loading of chemotherapeutic drugs, DNA, polymers, PS etc, by non-covalent 
method. Non-covalent bonding process involves hydrophobic interaction, π-π 
interactions, Van der Waal’s force of attractions. SWCNTs without any functional 
groups with hydrophobic nature and the loading molecules interact with non-polar 
attraction absorb on the walls of SWCNTs (Shi et al., 2014). Van der Waal’s force 
involves dipole interaction between the nanoparticle and PS molecule by 
intermolecular force, which facilitate to the PS aggregated on the surface of the 
nanoparticle. Both mechanisms are not well preferred in drug delivery system 







π-π stacking is another physical adsorption method to load PS on the 
nanoparticle. SWCNTs has aromatic ring carbon particle when the PS molecule 
has similar structure both stack on the surface and non-covalent bonding 
interaction takes place by π bonds. Hence, this mechanism named as π-π 
stacking. The long chain polymers or peptides will fold on the nanoparticles by 
π-π stacking to load drugs (Chen et al., 2001).  
 
The advantages of non-covalent bonding there is no structural damage of the 
drugs; the properties of the nanoparticle will remain the same (Bilalis et al., 2014; 
Besteman et al., 2003). Most of the PS molecules such as m-tetrahydroxyl 
phenylcholrin (mTHPC), Zinc phthalocyanine, Zinc monoaminophthalocyanine, 
Chlorin e6 are coupled non-covalently by π-π stacking to treat various cancer 
cells using phototherapy, commonly PDT and PTT are used in cancer cells 
(Ogbodu et al., 2013; Wu et al., 2017). In recent study, Single walled carbon 
nanotubes were coupled with encapsulated albumin chlorin e6 PS molecule by 
the ultra-homogenization technique for PTT has effect on squamous cell 
carcinoma (SCC 7) cell lines for in vitro and the in vivo studies on BALB/c nude 
female mice model (Xie et al., 2016).  
 
2.4.4.2. Chemical loading mechanism 
The covalent functionalization is like a defect in the sidewalls of nanomaterial, 
there will be an addition of different functional groups (Park et al., 2006). The 
main aim of the covalent functionalization is to avoid change in physical 
properties such as solubility, purity, sp² and sp³ hybridization of carbon 
molecules. Those properties of carbon make wide application in the field of 
medical science and nanotechnology (Zhang et al 2008). The functional groups 
are added to the CNTs such as carboxyl group, hydroxyl, amine, fluoride, 
disulphide bonds (Banerjee et al., 2005). The carboxyl group and amine group of 
Polyethylene glycol (PEG) coupled using EDC-NHS method to act as high 
loading nanocarrier. Due to the solubilizing nature and biocompatibility of the 
functionalized carbon nanomaterials, it is opted to add different polymeric chains, 
proteins, DNA and drugs (Zhang et al., 2011b). In recent study, 






and in vivo using PDT. The single walled carbon nanotubes covalently 
functionalized composite showed excellent photo cytotoxic action against cancer 
cells, the activity of the composite was based on the functionalization method 
(King et al., 2014). The loading mechanism of PS on SWCNTs were shown in 
Figure 2.11. 
 
Figure 2. 11 Loading mechanism of PS on SWCNTs. (The attachment of the PS 
molecule on aromatic rings of CNTs by π–π stacking, and the carboxyl group into 
amide formation of PS on the walls of CNTs, followed by the molecules being 
subjected to PDT. (CNTs-carbon nanotubes, PS-photosensitizers, PDT-
photodynamic therapy, COOH-carboxyl group, CONH-amide group). (Sundaram et 
al., 2020b). 
 
2.5. Combined Effects of Nanotubes and Photodynamic Therapy 
The cancer nanomedicine has both positive and negative response in terms of 
overcome the barriers in clinical translation. In drug delivery systems, the 
fundamentals of nanoparticles interaction with biological substances are not 
clearly reported (Editors, 2019). PDT widely used in various cancer types with 
minimal invasive and non-invasive treatment, and then low cumulative toxicity 
and no drug resistance. PDT application has some challenges to achieve 






molecule could cause photosensitization on skin, after treatment patients must 
stay in dark for several weeks, lack of tumour selectivity and accumulate in 
normal tissues leads to toxic effects (Dolmans et al., 2003; Li et al., 2018).  
Nanomedicine offers potential benefits in drug delivery systems such as 
bioavailability, protect drug degradation, and improve targeting the cells, 
regulated drug release at specific site, therapeutic efficacy with minimum side 
effects (Singh et al., 2020). Combined effects of nanomedicine and PDT mainly 
focused to overcome the side effects of the cancer treatments 
 
In recent study, PS coupled SWCNTs reported increased cytotoxic effect on 
breast cancer MCF-7 cell line and the combination therapy proved to be an 
effective therapy to treat breast cancer with reduced side effects (Ogbodu et al., 
2015a). The SWCNTs molecules are covalently carboxyl amine linking with anti-
CD133 markers to target the Glioblastoma stem-like cells, the photothermal 
effects of SWCNTs at 808 nm can effectively kill the targeted cells (Wang et al., 
2011). Very few studies have been performed using SWCNTs in the PDT listed 
in table 2.7. 
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(Lei et al., 2014) 
SWCNTs Chlorin e6 PDT Cervical cancer 
(HeLa cells) 











In this study, nanobiocomposite was prepared using SWCNTs functionalised HA 
to target CD44 receptors and coupled with Ce6 molecule for photodynamic 
effects to treat CCSCs. The stability, controlled release and localisation of 





























CHAPTER 3                              METHODOLOGY 
3.1. Synthesis of Nanobiocomposite 
Purchased commercially available carboxyl acid functionalised SWCNTs (Sigma 
Aldrich, 652490), HA (Sigma Aldrich, 40583), Ce6 (Santa Cruz biotechnology, 
CAS 19660-77-6). 
 
3.1.1. Purification of SWCNTs 
SWCNTs were treated using 12M Nitric acid (HNO3) (Sigma Aldrich, 438073) to 
get purified form of SWCNTs, then washed thoroughly with Milli-Q water (Thermo 
scientific, Barnstead, smart pure) and the filtration process using Stericup quick 
release-GP sterile vacuum filtration system, membrane filter pore size 0.22 µm 
(Merck, S2GPU05RE). 
3.1.2. Synthesis of Hyaluronic acid coupled SWCNTs (SWCNTs-HA) 
Hyaluronic acid added into dimethyl formamide (DMF) (Sigma Aldrich, 227056) 
and dispersed completely by sonication (Branson 1800). To activate the amine 
group of HA EDC/NHS method were followed: N-ethylcarbodiimde hydrochloride 
(EDC.HCl) (Sigma Aldrich, E6383) and N-hydroxysuccinimide (NHS) (Sigma 
Aldrich,130672) added to the HA dispersed solution by stirring 30 mins at room 
temperature, then added triethylamine 99 % (Sigma Aldrich, T0886) drop by drop 
and kept cool using ice bath and the solution was stirred and kept at room 
temperature for 2 h, which activated the HA. The reacted product was collected 
in membrane filter (D9777, Sigma-Aldrich) through rinsing repeatedly with 
acetone. The activated HA was dialysed for 48 h to remove acetone and 
unreacted EDC.HCl and NHS. The SWCNTs-COOH and HA-NH2 were added 
into formamide, sonicated for 10 min, EDC.HCl and NHS were added, and then 
it was stirred at room temperature for 15 min. After that, 180 mL of triethylamine 
was added drop by drop in the ice bath and reacted at room temperature for 24 
h. The reaction solution was cooled with excess precooled acetone and 
centrifuged at 10,000 rpm for 15 min. Finally, the precipitation was dissolved with 
water and dialyzed by a dialysis bag for 48 h to remove free HA and the 
synthesised products. 






The non-covalent binding of Ce6 on the walls of SWCNTs was achieved by the 
π-π interaction technique. Ce6 and HA-SWCNFTs were dissolved in DMF. The 
solution was then sonicated for 10 min. The mixture was stirred overnight and 
kept at RT. The final product was filtered using membrane filters (0.22 µm) and 
rinsed with DMF solution to remove unloaded Ce6. The final solution was then 
rinsed with milli-Q water and acetone to remove residual DMF. 
3.2. Characterisation of Newly Synthesised Nanobiocomposite 
3.2.1. Solubility study 
The synthesised nanobiocomposite and purchased SWCNTs were dispersed in 
1 mL of milli-Q water and stirred for 15 mins at room temperature using Eppendorf 
stirrer. The aggregation and solubility of the samples were observed and 
captured in photograph.   
3.2.2. Determination of activation wavelength  
The absorption peak for the synthesised nanobiocomposite were measured 
using UV-visible spectrophotometer (Genova 7315, Life Science 
Spectrophotometer, JENWAY). The spectral analysis for SWCNTs, HA, Ce6 and 
the final compound SWCNTs-HA-Ce6 were measured against milli-Q water in 1 
mL UV fused quartz cuvette, the whole experiments carried at the resolution of 1 
nm from 200 to 800 nm. 
3.2.3. Fourier Transformation Infra-red spectroscopy (FTIR) 
The FTIR spectroscopy analysis was used to identify the chemical shifts and 
functional groups present in the compound. Moreover, potassium bromide (KBr) 
was used as well as the Hydraulic Pellet Press method to produce a thin sample 
of KBr pellet that was then subjected to FTIR analysis. The synthesised 
nanobiocomposites, SWCNTs, HA, Ce6 and SWCNTs-HA were added on the 
surface of pelleted KBr to measure FTIR spectroscopy. The frequency range was 
measured as wave numbers, typically over the range 4000–500 cm-1 using the 
JASCO FT/IR-6300 Series, Japan. 
 






The X-ray diffraction measures structures of crystalline compounds and surface 
chemistry. The XRD patterns were determined using a diffractometer equipped 
with a rotating target X-ray tube and a wide-angle goniometer. The X-ray source 
were Kα radiated from a copper target with a graphite monochromator. The X-
ray tube was operated at a potential of 45 kV and a current of 40 mA. The range 
(2 θ) of scans was performed from 10to 80 at a speed of 4 per min at increments 
of 0.05. The XRD pattern were analysed for SWCNTs and SWCNTs-HA-Ce6 
using the Rigaku Ultima lV instrument and the data were collected from PDXL 
analysis software (Tokyo, Japan). 
3.2.5. Particle size and zeta potential 
The synthesised nanobiocomposite size distribution (hydrodynamic diameter) 
and Zeta potential were studied by the dynamic light scattering (DLS) method 
(Zeta sizer ver. 7.10, Malvern Instruments Ltd., Malvern, UK). The scattering 
intensity was adjusted in the range of 50-500 kcps and the samples were diluted 
using Millipore water, measurements were carried out using disposable cuvettes 
(DT S0012) in triplicate. For the light method, samples were measured at a fixed 
angle of 90° at 25 °C. 
3.2.6. High resolution transmission electron microscope (HR-TEM) 
Morphological evaluation of the synthesised nanobiocomposite done by HR-
TEM. SWCNTs, SWCNTs-HA and SWCNTs-HA-Ce6 samples were measured 
about 10 µg and dispersed in ethanol, then sonicated in ultrasonic bath for 
15mins. Prepared samples were drop-casted separately on carbon-coated 
copper TEM grid dried it for 10 mins. HR-TEM images recorded on JEOL JEM 
2100F operated at an accelerating voltage of 200 kV. 
3.3. Stability Study 
The stability of the newly synthesised nanobiocomposite was determined using 
the two different pH (5.5 & 7.4) of PBS solution at room temperature. Ce6 and 
SWCNTs-HA-Ce6 was measured 1 mg/mL in the eppendorf tubes and dispersed 
in PBS solution, maintained in shaker at 37 °C. In various physiological conditions 
the stability of the nanobiocomposite at different time interval the samples were 







3.4. Photosensitizer Ce6 Loading and In Vitro Release Study 
The photosensitizer loading efficiency on the SWCNTs-HA were calculated using 
the amount of unbound Ce6 from the synthesis process. The final solution of the 
synthesis process collected and unbound Ce6 determined using UV-visible 
spectrophotometer measured the absorbance at 660 nm. The measured values 
are calculated using the formulae 
𝑃𝐿𝐸 ( %) =
𝑤𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑙𝑜𝑎𝑑𝑒𝑑 𝑃𝑆 
𝑤𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑃𝑆 𝑖𝑛𝑓𝑒𝑒𝑑
 × 100 
The photosensitizer release study was carried out using the dialysis technique, 
the release behaviour of the Ce6 from SWCNTs-HA-Ce6. The newly synthesised 
nanobiocomposite dispersed in phosphate buffer saline (PBS) pH 7.4 and pH 5.5 
and then the solution transferred into the dialysis membrane tubes. The dialysis 
membrane tubes were submerged in 200 mL of PBS with 0.1 % (W/V) tween80 
(P1754, Sigma-Aldrich) and kept in gentle shaker at 37 °C. To analysis the 
released Ce6 from the dialysis bag 1 mL of the release medium taken in the new 
eppendorf tubes in predetermined time and replaced by 1 mL of fresh medium 
each time. The amount of released Ce6 from SWCNTs-HA-Ce6 measured using 







Figure 3. 1 Dialysis bag unit for drug release study. 
 
The in vitro release studies data was analyzed using different mathematical 
models to study the mechanism of release. The studied mathematical models are 
Zero order kinetic (Eq.1), First order kinetic (Eq. 2), Higuchi kinetic (Eq.3), and 
Korsmeyer-Peppas model (Eq. 4).  
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The plots were made of percentage of drug release, Qt Vs time (zero order kinetic 
model), log percentage drug remaining Vs time (first-order kinetic model), 
percentage of drug release, Qt Vs square root of time (Higuchi model) and Log 
cumulative percentage drug released Vs Log Time (Korsmeyer-Peppas model) 
(Gouda et al., 2017).  
 
where Qt is the percent of drug released at time t, Q0 is the initial amount of drug 
present in the nanotubes, Mt is the fraction of drug released at time, t and n is 
the diffusional exponent for drug release, K0, K1, K H and KP the rate constants 
of the equations 1,2, 3 and 4 respectively. 
 
3.5. Cell Culture 
Colon cancer cell line Caco-2 was purchased from ATCC®, HTB-37™ and 
cultured in Dulbecco’s modified eagle’s medium (DMEM) (sigma-Aldrich) 
supplemented with 10 % (v/v) foetal bovine serum (FBS) (F9665-Sigma-Aldrich), 
2 mM L-glutamate (G7513, Sigma-Aldrich). Cultured cells were incubated at 37 
°C in 5% CO2 and 85 % humidity in tissue culture flasks. When the cells are 
reached 90 % confluence, cells were washed twice with Hank’s balanced salt 
solution (HBSS) (14065-056, Gibco) and to detach the cells from cultured flask 
TrypLE Express (12604, Gibco) was used. 
 
3.5.1. Viability of cells using trypan blue assay 
It is essential to quantify the number of cells and check their viability before 
conducting all the experiments. An automated cell counter, Countess® II 
(Invitrogen) was used for this purpose. The machine counts and differentiates 
live from dead cell by trypan blue exclusion test which is based on the principle 
that viable cells do not take up impermeable dyes (like Trypan Blue), but dead 
cells are due to damaged membranes, take up the dye. A 1 mL cell suspension 
as described previously was mixed properly using a vortex shaker. 10μLof the 
well mixed cell suspension was added to an equal volume of 0.4% trypan blue 
solution (Sigma Aldrich.) in a 1 mL test tube. The mixture could stain for 5 min at 
room temperature in the dark to avoid photo-bleaching of the dye. After staining, 






sample mixture. Upon insertion of the slide unto to the slide reader, the 
instrument automatically illuminates the sample and focuses the cells. After the 
cells were fully focused, automatically and manually when necessary, the capture 
button was pressed to read the measurement. The instrument captures the 
image and displays the results including the total cells concentration per mL, and 
the percentage of live and dead cells with their concentration per mL. Both sides 
of the slide were analyzed and the average of the two counts was used as the 
cell count. 
 
3.6. Intracellular Localisation of SWCNTs-HA-Ce6 
To localize the newly synthesised nanobiocomposite using sub-cellular trackers. 
5×105 Caco-2 cells were cultured on the sterile glass cover slips (0895202, 
MARIENFELD) with complete medium in treated culture dishes (45 CLS430588, 
Sigma), after attachment of cells SWCNTs-HA-Ce6 was added into the medium 
and incubated at 37 °C in 5% CO2 and 85 % humidity. After 12 h the cells were 
thrice rinsed using HBSS to remove unbound Ce6 and SWCNTs-HA-Ce6. Added 
500 µL of 4 % paraformaldehyde (P6148, Sigma-Aldrich) on the cells and 
incubated for 20 mins at 37 °C to fix the cells, then rinsed twice using HBSS. For 
permeabilization 200 µL of 0.2 % triton X-100 (Sigma Aldrich, T9284) added on 
the cells and incubated for 10 mins at 37 °C, then rinsed twice using HBSS. 
Prewarmed staining solution of mito tracker 100 nM (M7514, Invitrogen) and lyso 
tracker 50 nM (L7526, Invitrogen) were added on the cells and incubated for 30 
mins at 37 °C, then rinsed twice using HBSS. For counter staining 300 nM 4’, 6-
Diamidino-2-Phenylindole, Dihydrochloride (DAPI) (D1306, Invitrogen) was 
added and incubated for 20 mins at 37 °C, then washed twice using PBS. The 
glass cover slip was taken out and dried for 5 mins using Fluoromount™ Aqueous 
Mounting Medium (F4680, Sigma-Aldrich) the cover slip mounted on the glass 
slide (GLAS4S22M3000F, Lasec) and visualized using Carl Zeiss live imaging 
microscope (Axio Observer Z1).   
 
3.7. PDT Effect of Swcnts-HA-Ce6 on Colon Cancer Cell Lines 
The red-light lasers were obtained from the National Laser Centre of South Africa. 






(FieldMate, Coherent, Power sens detector) and the laser parameters are 
tabulated in table 3.1. The cells were cultured in a 3.4 cm petri dish where the 
laser spot size covers the monolayer of cells. The height of the light source was 
8 cm above the cells. To treat the cancer cells, red light lasers were used at the 
wavelength of 660 nm, which is the excited range of the Ce6 photosensitizer. The 
cells were divided into three groups: group 1: cells alone and cells with SWCNTs, 
Ce6 and SWCNTs-HA-Ce6 without treatment; group 2: cells alone and cells with 
SWCNTs, Ce6 and SWCNTs-HA-Ce6 with treatment of fluence 5 J/cm2; group 
3: cells alone and cells with SWCNTs, Ce6 and SWCNTs-HA-Ce6 with treatment 
of fluence 10 J/cm2.  
 
3.7.1. Morphology  
The live and dead cell morphology before and after irradiation was viewed under 
a CKX41 inverted light microscope (Olympus, Wirsam) connected to a camera 
with analysis getIT software. 
3.7.2. Cytotoxicity 
The cytotoxicity level of the samples was estimated using Cyto Tox 96® Non-
Radioactive cytotoxicity assay. The CytoTox 96® assay quantitatively measures 
the lactate dehydrogenase (LDH), which was released from cells during lysis. 
Fifty microliters of control and test samples were added in a 96 well plate and the 
same amount of LDH reagent was added in the wells, then incubated in the dark 
at room temperature for 30 min. The colorimetric compound was measured 
spectrophotometrically at 490 nm using a multilabel Counter (Perkin Elmer, 
VICTOR3— Multilabel Plate Reader, 1420). We adopted the same methodology 
to find out the IC50 concentrations of synthesized nanobiocomposite. 
 
3.7.3. Cell Death 
The assay uses Annexin V–fluorescein isothiocyanate (FITC) and propidium 
iodide (PI) (556547, BD Biosciences) to identify phosphatidyl serine sites on the 
membrane of apoptotic cells, as well as sites of membrane damage in necrotic 
cells, respectively. The assay was done according to the manufacturer’s 






FITC was detected as green fluorescence and PI as red. After treatment and 
incubation, the cells from all groups were detached and washed with Hanks 
Balanced Salt Solution. Cells were resuspended in the 1X binding buffer at a 
concentration of 106 cells/mL, and 100 µL of the cell suspension was transferred 
into flow cytometry tubes. Five microliters each of the Annexin V–FITC and PI 
reagents were added, and the tubes were thoroughly mixed and incubated for 10 
min at RT in the dark. Flow cytometric analysis was performed within one hour at 
a rate of 400 events per second with a limit of 350 µL for each sample. Data 
acquisition proceeded until 10,000 events were obtained for every sample. Data 
was analysed on the BD C Sampler software. 
3.8. Isolation of Colon Cancer Stem Cells 
Colon cancer stem cells also known as side population of colon cancer cell lines, 
CCSCs were isolated from Caco-2 cell lines using magnetic activated cell sorting 
MACS (Miltenyi Biotec). CD133 (130-050-801, microbead kit, Miltenyi Biotec), 
CD44 (130-095-194, microbead kit, Miltenyi Biotec) and CD24 (130-095-951, 
microbead kit, Miltenyi Biotec) markers are used to isolate the side population 
from the Caco-2 cell line. The positive selection of CD133+, CD44+ and CD24+ 
cells was separated using QuadroMACS™ based on the principle of monoclonal 
antibody and specific antigen interactions. 
  
Caco-2 cells was cultured in 175 cm2 T-flask incubated at 37 °C in 5% CO2 and 
85 % humidity, when it reached 80 % confluence, the cells were washed twice 
using HBSS and detached using TrypLE express. The detached cell number and 
viability were determine using trypan blue stain, 0.4% (T10282, Invitrogen™) and 
measured on a Countess™ II automated cell counter (AMQAX1000, 
ThermoFischer). According to the MACS protocol cells were resuspended to the 
concentration 1×107 cells and centrifuged at 3000 rpm for 10 mins. The supernant 
was discarded and the cell pellet was resuspended in isolation buffer (PBS 7.2, 
0.5% BSA, 2mM EDTA). 
 
Fragment crystallizable receptor (FcR) blocking buffer to avoid unwanted binding 
of antibodies, 80 µL of FcR buffer was added on each tube and gently mixed by 






suspension mixed well and incubated on ice for 30 mins at dark condition on a 
shaker. After exposure to antibodies, the cells were washed using buffer solution 
and centrifuged at 3000 rpm for 10 mins, the supernatant aspirated completely, 
and the cells resuspended with buffer solution. 
  
Isolation of SCs, MACS LS columns were used. LS columns were placed on the 
magnetic field of the QaudroMACS™ Separator, to rinse the LS column initially 
3 mL of buffer run through the LS columns and the cell suspension was added 
onto the column left undisturbed. CD133+ cells attached on the walls of LS 
column and unbound cells washed with buffer solution and collected in empty 
vials. For positive cells using a LS column plunger 3 mL of buffer solution added 
on the LS column then flushed out by pushing the plunger into the LS column. 
Positive selected cells were cultivated using ultra-low attachment flasks to 
maintain the spheroids and prevents differentiation of CSCs. To grow the CCSCs 
complete stem cell media DMEM-F12 supplemented with 0.4% FBS, 20 ng/mL 
epidermal growth factor (EGF), 20 ng/mL basic fibroblasts growth factor (bFGF) 
was used.  
 
3.9. Characterisation of Isolated Colon Cancer Stem Cells 
3.9.1. Spheroid formation 
The isolated were incubated in complete stem cell medium at 37 °C in 5% CO2 
and 85 % humidity in ultra-low attachment flask. The flask was viewed under light 
microscope in time interval and captured the spheroid formation images. 
 
3.9.2. Flow cytometry 
To confirm the isolated side population, were origin of CSCs using fluorescently 
labelled antibodies conjugation method identified by flow cytometry. The 
cultivated cells were rinsed twice with HBSS and detached using TrypLE express 
and then washed twice using washing buffer then incubated with blocking buffer 
for 1 hr at 37°C after that washed twice using washing buffer. Primary antibodies 
mouse anti human CD44 (MABF425, human/mouse, PE-Cy5, clone IM7, Sigma-
Aldrich), CD133 (130-133-673, AC133, Vio® Bright FTIC, Miltenyi Biotec) are 






555426, human/mouse, clone ML5, BD Biosciences) indirect 
immunofluorescence method. 
The antibodies were diluted using working buffer and added into the cell 
suspension was incubated for 1 hr at 4°C under dark condition, then the cell 
suspension was washed trice using washing buffer. For CD24 alone 
fluorochrome conjugated secondary antibodies Cy5 goat anti-mouse (Novus Bio, 
NB7602) were added into the working buffer incubated for 30 mins at 4°C under 
dark condition, then cell suspension washed trice using washing buffer. Finally, 
the cell suspension subjected to analyse using C6 flow cytometer (BD 
Biosciences, BD ACCURI C6 PLUS) which detect the fluorescent probes on the 
cell surface. These results indicate the positive and negative selection of CD44, 
CD133 and CD24 markers on the surface of isolated CCSCs.  
 
3.9.3. Immunofluorescence (IFL) 
The isolated CCSCs was characterised using direct and indirect 
immunofluorescence method. In direct IFL, the primary antibody conjugated with 
fluorochromes to visualise CCSCs. In-direct IFL CCSCs are labelled using 
primary antibodies to target specific antigen and fluorochromes conjugated 
secondary antibodies directed towards primary antibodies, this fluorescence 
visualized under live microscope. CCSCs were cultured on sterile coverslips 
placed in culture dishes, at a concentration of 5×105 cells in complete stem cell 
media. 
 
Once the cells reached confluence discarded the media and rinsed twice with 
ice-cold washing buffer (PBS, 0.1% BSA, 0.01% Sodium azide). For fixation of 
cells 4% paraformaldehyde was added and incubated for 20 mins at 37 °C, then 
rinsed twice using washing buffer. After fixing the cells, to permeabilize the cells 
0.1 % Trixton X-100 was added and incubated for 10 mins at 37°C, then rinsed 
twice using washing buffer. Blocking buffer (10% BSA) was added and incubated 
for 1 hr at 37°C and washed twice using washing buffer.  
 
Cells were then incubated with 100 µL of primary antibodies anti human CD44 






1013, human/rabbit, clone F8, ZooAb, Merck) and CD24 (# 555426, 
human/mouse, clone ML5, BD Biosciences) in working buffer (PBS, 2% BSA, 
0.01% Sodium azide) overnight incubation at 4°C, to protect from dryness the 
petri dishes are placed on wet bed and maintained dark condition. The cells were 
then washed trice using washing buffer.  
 
The washed cells were incubated with 100 µL of secondary antibodies FTIC 
(Santa Cruz biotechnology, mouse anti-rabbit IgG, Sc 2359), Cy5 (Novus Bio, 
NB7602) goat anti mouse antibodies in working buffer for 1 hr at 4°C maintain 
dark condition and the cells were washed twice using washing buffer. CD 44 was 
direct IFL process so that skipped the introduction of secondary antibody into the 
plates. To counter staining 300 nM DAPI was added and incubated for 20 mins 
at 37°C, then washed trice using washing buffer. Finally, the coverslips were 
taken from the plates using tweezers, dipped in distilled water to remove residual 
and mounted on the microscope slides using mounting media. The slides were 
visualized under Carl Zeiss Axio Z1 microscope.  
 
3.10. Targeted Delivery of SWCNTs-HA-Ce6 
The isolated CCSCs were cultured on glass cover slip containing petri dish and 
incubated at 37 °C in 5% CO2 and 85 % humidity.  As control cells CD44 negative 
SK-UT-1 (ATCC ® HTB 114™) cells also cultured with MEM complete medium. 
Once the cells reached confluency incubated with SWCNTs-HA-Ce6 for 4 h and 
thrice rinsed using HBSS to remove unbound SWCNTs-HA-Ce6. Added 500 µL 
of 4 % paraformaldehyde (P6148, Sigma-Aldrich) on the cells and incubated for 
20 mins at 37 °C to fix the cells, then rinsed twice using HBSS. For 
permeabilization 200 µL of 0.2 % triton X-100 (Sigma Aldrich, T9284) added on 
the cells and incubated for 10 mins at 37 °C, then rinsed twice using HBSS. 
Prewarmed staining solution of mito tracker 100 nM (M7514, Invitrogen) were 
added on the cells and incubated for 30 mins at 37 °C, then rinsed twice using 
HBSS. For counter staining 300 nM 4’, 6-Diamidino-2-Phenylindole, 
Dihydrochloride (DAPI) was added and incubated for 20 mins at 37 °C, then 






using Fluoromount™ Aqueous Mounting Medium the cover slip mounted on the 
glass slide and visualized using Carl Zeiss live imaging microscope. 
 
3.11. Photodynamic Therapy on Isolated CCSCs 
The red light-lasers were purchased from the National Laser Centre of South 
Africa (NLC). The laser output power was measured using a FeidMate Laser 
Power Meter (Coherent, 1098297) and a high-sensitivity thermopile sensor PM3 
(Coherent, 1098336). Based on the measured power and selected fluence using 




















The isolated CCSCs were cultured in a small petri dish (3.4 cm) and incorporated 
with newly synthesised nanobiocomposite after attachment of cells. The treated 
laser parameters are summarized in Table 3.1 
Table 3. 1 Laser parameters. 
Parameters  
Laser type Semiconductor diode 
Wavelength (nm) 660 
Emission Continuous wave 
Fluences (J/cm2) 5 and 10 
Irradiation time 7 min 16 s 
14 min 32 s 
Photosensitizer Chlorin e6 







When the cells reached confluency, treated with red light lasers at 660 nm which 
is the excited range of Ce6, the whole treatment was carried at dark condition. 
The cells where divided into groups explained in Table 3.2 
Table 3. 2 Experimental groups used in the present study. 
 
Groups Description Number of plates 
Group A 0J/cm2 1- Only cells 
2- Ce6 alone 
3- SWCNTs-HA-Ce6 
Group B 5J/cm2 1- Only cells 
2- Ce6 alone 
3- SWCNTs-HA-Ce6 
Group C 10J/cm2 1- Only cells 
2- Ce6 alone 
3- SWCNTs-HA-Ce6 
 
3.11.1. Morphology studies 
The treated cells morphology was visualized using CKX41 inverted light 
microscope (Olympus, Wirsam) connected to a camera with getIT software. After 
PDT 0 h, 24 h and 48 h morphology (live and dead cells) of each plate were 
captured.   
 
3.11.2. Cytotoxicity assay using lactate dehydrogenase (LDH) assay 
To measure the cytotoxicity range of synthesised nanobiocomposite under PDT 
treatment using LDH assay. when the cell membrane damaged induces to 
leakage of LDH through plasma membrane rapidly released into the cell culture 
medium. CytoTox 96® Non-Radioactive Cytotoxicity colourimetric assay (G1780, 
Promega), LDH reacts to convert a tetrazolium salt (in the reconstituted reagent, 








The PDT treated cells were incubated for 24 hrs and 48 hrs at 37 °C in 5% CO2 
and 85 % humidity, then the 50 µL of medium from cells and 50 µL of 
reconstituted reagent mixed together in flat bottom 96 well clear polystyrene 
microplate (CLS3370, Corning®, Merck). The microplate was incubated for 30 
mins at room temperature in the wave motion mixer and the compound measured 
using VICTOR3 multilabel plate counter. 
 
3.11.3. Flow cytometry Annexin V–fluorescein isothiocyanate (FITC) 
and Propidium Iodide (PI) 
To measure the cell death events and cell populations (normal or dying cells) 
FTIC Annexin V Apoptosis detection kit I (556547, BD Pharmingen™) was used. 
After 24 hrs and 48 hrs post irradiation the cell death was measured using flow 
cytometry to identify phosphatidyl serine sites on the membrane of apoptotic cells 
or membrane damage in necrotic cells. The treated cells were rinsed with HBSS 
and detached using TrypLE express, cells suspension was transferred into flow 
cytometry tubes and resuspended with 1X binding buffer. 5 µL of Annexin V-FTIC 
and PI reagents added into the cell suspension and mixed thoroughly incubated 
for 10 mins at room temperature under dark condition. Finally, the C6 flow 
cytometric analysis was performed to detect the FTIC green and PI red 
fluorescence respectively.  
 
3.11.4. Determination of metabolic activity of cells using Adenosine 
Triphosphate (ATP) luminescence assay 
The PDT treated cells incubated for 24 hrs and 48 hrs at 37 °C in 5% CO2 and 
85 % humidity and to quantify the amount of ATP presence in the cells using 
CellTiter-Glo® 2.0 ATP luminescence assay (Promega, G9241). ATP 
luminescence assay was homogenous method to determine the amount of ATP 
in the cultured cells is directly proportional to the viable cells. 
 
PDT treated cells were rinsed with HBSS and detached using TrypLE express, 
then centrifuged at 3000 rpm for 5 mins and collected pellets. In white polystyrene 
96well plate (CLS3912, Corning®, Merck) 50 µL of cell suspension and 50 µL of 






(Polymax 1040, Heidoplh) for 2 mins to induce cell lysis and incubated for 10 
mins at 37°C under dark condition, for baseline control complete media was 
added to test. The luminescent signal was measured in relative light units (RLUs) 
using multilabel plate counter (1420, VICTOR3™, Perkin Elmer).  
 
3.11.5. Nuclear damage study 
To determine the nuclear damage of the treated cells was measured using live 
cell fluorescent microscope using Hoechst dye 33342 (H357, Invitrogen). CCSCs 
were cultured on sterile coverslips placed in culture dishes, at a concentration of 
5×105 cells in complete stem cell media. After attachment of cells, newly 
synthesised nanobiocomposite was incorporated into the cells and irradiated at 
660 nm and incubated for 48 hrs at 37 °C in 5% CO2 and 85 % humidity. The 
incubated cells were rinsed twice with HBSS and added 500 µL of 4% 
paraformaldehyde incubated for 20 mins at 37 °C then washed twice using PBS 
solution. Cells were incubated with 1 µg/mL of Hoechst dye for 10 mins at 37 °C 
under dark condition, after incubation period cells were washed twice using PBS 
solution. For counter staining PI was added and incubated for 15 mins at 37 °C 
under dark condition, then washed with PBS solution. The coverslip was mounted 
on the glass slip using Fluoromount media and visualised under live cell 
microscope. 
 
3.11.6. Intracellular reactive oxygen species detection 
To determine the production of ROS using fluorometric intracellular ROS kit 
(MAK142, Sigma-Aldrich). It is one step fluorometric assay to detect free radicals’ 
superoxide and hydroxyl in live cells. ROS reacts with a fluorogenic sensor 
localised to the cytoplasm and produce the fluorescence is proportional to the 
amount of ROS present. CCSCs were cultured on sterile coverslips placed in 
culture dishes, at a concentration of 5×105 cells in complete stem cell media. After 
attachment of cells, newly synthesised nanobiocomposite was incorporated into 
the cells and irradiated at 660 nm and incubated for 1 hr at 37 °C in 5% CO2 and 
85 % humidity.  
Cells were rinsed with HBSS and ROS master mix 100 µL was added into the 






and 300 nM DAPI was added into the cells incubated for 20 mins at 37 °C. The 
coverslip mounted on the glass slide using fluoromount and visualised using live 
cell microscope. 
 
3.12. Statistical Analysis 
The results were obtained, processed for graphic presentation, and data analysis 
was done with Origin Pro 8 SRO (v8.0724) and BD CSampler™ software. All 
experiments were done in triplicate to monitor for the reproducibility of the results, 
and all data is expressed as the mean ± standard deviation. Difference between 




























CHAPTER 4                  RESULTS AND DISCUSSION 
 
4.1. Synthesis of Nanobiocomposite Using SWCNTs, HA and Ce6 
SWCNTs were recently introduced as nanocarrier for biomedical applications, 
due to the physicochemical characteristics, wide surface area and excretion from 
body through urine without damaging any cells and tissues (He et al., 2013). In 
this work, we successfully synthesized functionalized nanobiocomposite 
(SWCNTs-HA-Ce6) using carboxylated SWCNTs and biopolymer HA, and 
natural PS molecule Ce6.  The carboxyl group of SWCNTs and amine activated 
HA chemically attached by strong carbonyl bond. Carboxylated SWCNTs were 
successfully coupled with HA by covalent bonding mechanism of carboxyl amine 
cross-linking (Hou et al., 2015). When the CNTs are coupled with polymers or 
proteins, it shows excellent water dispersibility, biocompatibility and sustained 
stability, those are some of good qualities of nanocarrier (Xu et al., 2008).  
SWCNTs-HA molecule non covalently coated with naturally derived PS molecule 
Ce6 by π-π interaction. It is well-known that electron rich molecules easily form 
π-π interaction with another electron rich compound, those bonding were very 
strong in nature (Liu et al., 2019). Ce6 molecule is hydrophobic and electron rich 
molecule like SWCNTs easily bind by π-π interaction (Xiao et al., 2012). The 
newly synthesised nanobiocomposite were confirmed by various 
physicochemical characterisation techniques as discussed in section 4.2. 
4.2. Physicochemical Characterisation of Newly Synthesised 
Nanobiocomposite 
4.2.1. Dispersibility analysis of newly synthesised nanobiocomposite 
Dispersibility studies for all the samples were performed by dissolving 1 mg of 
SWCNTs and 1 mg of SWCNTs-HA-Ce6 with 1 mL of Millipore water separately 
and mixing it vigorously using vortex mixer, and the images of SWCNTs alone 
and SWCNTs-HA-Ce6 are illustrated in Figure 4.1. The SWCNTs and Ce6 are 
hydrophobic in nature, while the synthesised nanobiocomposite showed 









Figure 4. 1 Dispersibility analysis of nanobiocomposite. [a] SWCNTs, [b] SWCNTs-
HA-Ce6. 
 
4.2.2. UV Spectrophotometer study 
4.2.2.1. Spectrum analysis of different concentration of Ce6 
In order to find out the maximum absorbance peak for Ce6, the different 
concentration of Ce6 compound was taken and dissolved into the DMF solvent. 
The UV spectral analysis of Ce6 showed three characteristics peaks at 405 nm, 
503 nm and 664 nm and this result correlate with reported studies by Xiao et al., 








Figure 4. 2 Spectrum analysis of Ce6 at different concentration. 
 
4.2.2.2. Spectrum analysis of SWCNTs, HA, Ce6 and SWCNTs-HA-Ce6 
The spectrum analysis was carried out for SWCNTs, HA, Ce6 and SWCNTs-HA-
Ce6, and the major absorbance peak was measured using UV 
spectrophotometer. The UV major absorption peaks of SWCNTs, HA, Ce6 and 
SWCNTs-HA-Ce6 compounds are shown in the Figure 4.3. The absorbance 
peak of SWCNTs, HA, Ce6 and SWCNTs-HA-Ce6 were recorded from 200-800 
nm wavelengths. DMF solution was kept as a blank, since all the samples 
(SWCNTs, HA and Ce6) were dissolved in DMF solution. We observed the the 
maximum absorbance peak of SWCNTs was recorded at 268 nm (De Adhikari et 
al., 2009). The UV spectrum analysis for HA showed no characteristics peak in 
the absorbed ranges of 200-800 nm (Hou et al., 2015). 
The final synthesised compound SWCNTs-HA-Ce6 was dispersed in Millipore 






wavelengths. Here, Millipore water was used as a blank.  The characteristics and 
major absorption peaks of SWCNTs (268 nm) and Ce6 molecule (405, 503, and 
664 nm) were observed in the SWCNTs-HA-Ce6 compound. These results 
indicate the successful bonding of HA and Ce6 on the SWCNTs-HA-Ce6. 
 
Figure 4. 3 UV spectrophotometer of [a] SWCNTs, [b] HA, [c] Ce6, [d] SWCNTs-
HA-Ce6. 
 
4.2.3. Fourier transform infrared (FTIR) spectroscopy of the newly 
synthesised nanobiocomposite 
FTIR spectroscopy is an important and popular tool to examine the surface 






absorption frequency ranges, functional group and their bond shifting in FTIR 
spectrum.  SWCNTs, HA, Ce6 and SWCNTs-HA-Ce6 were analysed using FTIR 
spectroscopy and the spectrum peaks were recorded from 500-4000 cm-1. 
 
 
Figure 4. 4 Fourier transform infra-red spectroscopy spectrum of [a] SWCNTs [b] 






The FTIR spectra of SWCNTs, depicted as a black line spectrum from Figure 4.4, 
showed a strong carbon absorption bond peak of C=C at 2323 cm-1, =C–H at 
1980 cm-1, and carboxyl bond stretching C=O at 1752 cm-1 (Bagheri et al., 2017). 
In the brown line spectra, the board 3285 cm-1 stretching represents the amide 
bond and medium peaks at 1605 cm-1and 608 cm-1, the C–N minor stretching 
band observed at 1153 cm-1 (Hou et al., 2015) and 1040 cm-1 represents the 
functional group of C-O-C of HA. The Ce6 spectrum depicted as a green line 
shows a strong stretching vibration peak of the carboxyl group at 1709 cm-1 
(Gladkova et al., 2010), characteristics of O–H bands were observed at 3285 cm-
1 and 1234 cm-1, and the band range of 2964 cm-1and 1432 cm-1 indicates the C–
H bond. 
 
The FTIR spectrum (pink line) of SWCNTs-HA illustrates peaks at 2323 cm-1 
(C=C) that confirm the presence of basic functional units of a strong carbon 
absorption bond peak of SWCNTs, and the peaks at 1066 cm-1 confirm the 
presence of the COC functional group of HA (Kumar et al., 2015). The 
synthesised nanobiocomposite spectrum was depicted as a blue line; it showed 
the characteristic peaks of SWCNTs, HA and Ce6 with minor band shifts due to 
the functionalisation process. These results indicated the presence of the 
functional groups, the carboxyl amide bonds spectrum vibrations of SWCNTs, 
HA, and Ce6 were seen in the synthesised nanobiocomposite. 
 
4.2.4. X-ray diffraction analysis 
The crystallinity and structural properties of the nanosized particles were 
analysed using X-ray diffraction study. The obtained XRD results were compared 
with Joint Committee on Power Diffraction Standards (JCPDS) numbers. Both 
SWCNTs and SWCNTs-HA-Ce6 were deposited on a crystal silicon wafer for 
XRD analysis. The XRD patterns of the SWCNTs are shown in Figure 4.5 and 
indicate that the characteristic peak at 26.3° corresponds to C (002) planes, 
according to JCPDS # 751621 reflecting graphite. 
The plane 002 indicates the presence of SP2 bonded carbon arrangements of 
SWCNTs (Kumar et al., 2018). For the synthesised nanobiocomposite, there was 






002. This may be due to the coupling of HA and Ce6 on the surface of SWCNTs, 
and there were changes observed in the crystalline nature of the 
nanobiocomposite. These results confirm the addition of HA and Ce6 on the 
SWCNTs. 
 
Figure 4. 5 X-ray diffraction pattern of [a] SWCNTs, [b] SWCNTs-HA-Ce6. 
 
4.2.5. Zeta potential and particle size analysis by DLS method 
The zeta potential and particle size distribution were studied using the dynamic 
laser scattering technique (DLS) and the results are presented in Figure 4.6. Zeta 
potential measurements were used to characterise the surface charge and 
physical stability of the system. Particle size distribution was used to measure 
the size of the newly synthesised nanobiocomposite and in this study we 
compared the initial size of SWCNTs to the synthesised SWCNTs-HA-Ce6.  
The average size of the particles recorded was approximately 191 ± 4.6 nm for 






nanobiocomposite increased due the coupling of HA and Ce6 molecules. The 
zeta potential analysis for SWCNTs was −17.8 ± 1.2 mV and for SWCNTs-HA-
Ce6, it was −18.9 ± 1 mV. These results indicate that the SWCNTs and 
synthesized nanobiocomposite is stable. The stability of the nanoparticles is a 
crucial part of newly synthesised drug delivery systems, the zeta potential results 
strongly indicating the stability of SWCNTs-HA-Ce6. 
 
 
Figure 4. 6 Dynamic laser scattering technique for SWCNTs and SWCNTs-HA-Ce6. 
[a] particle size for SWCNTs [b] zeta potential for SWCNTs [c] particle size for 
SWCNTs-HA-Ce6 [d] zeta potential for SWCNTs-HA-Ce6. 
4.2.6. High-resolution transmission electron microscope (HR-TEM) 
High-resolution transmission electron microscope technique reveals the structure 
of nanosized particles, by passing the electron beam on the specimen to form 
the image of the object. Figure 4.7 shows the HRTEM images of SWCNTs, HA 








Figure 4. 7 Transmission electron microscope (TEM) images of [a] SWCNTs at 200 
nm [b] SWCNTs at 50 nm [c] SWCNTs-HA at 200 nm [d] SWCNTs -HA 50 nm [e] 






Figure 4.7a and c showed HRTEM images of SWCNTs at low and higher 
magnifications as can be seen by the scale bar of 200 nm and 50 nm, 
respectively. It shows that the SWCNTs were looks mostly smooth in surface, 
nanotubes were clumped together, and the sidewalls of the nanotubes are 
distinctly visible and free from aggregation (Xiao et al., 2012). Figure 4.7c & d 
showed the HRTEM images of SWCNTs-HA at low and higher magnifications 
respectively and Figure 4.7 e & f showed the HRTEM images of SWCNTs-HA-
Ce6 at low and higher magnifications respectively. In Figure 4.7 d and f, the 
surface of the nanotubes looks rough and the size of the sidewalls of the 
nanotubes were showed slightly larger than the plain SWCNTs (Figure 4.7b) and 
it may be due to the attachment of HA and Ce6 particles. The rougher surface 
morphology due to the attachment of HA molecule on the outer layer of SWCNTs. 
Then the Ce6 coated on the SWCNTs by π-π interactions on the walls of the 
SWCNTs. The structural form of SWCNTs-HA-Ce6 (Figure 4.7 e and f) 
morphology showed almost similar structure of SWCNTs (Figure 4.7 a and b) 
and no breaking or defects in the nanotubes. It elucidates that the structural 
morphology of SWCNTs are maintained throughout the synthesis process (Yao 
et al., 2014).  
 
4.3. Stability Analysis of Synthesised Nanobiocomposite 
The stability of Ce6 loaded nanobiocomposite in physiological environment (pH 
7.4) is considered as an important criterion in drug delivery studies. Similarly, the 
stability potential of released Ce6 from the nanobiocomposite in the intracellular 
environment (pH 5.5) facilitate the higher therapeutic activity of photodynamic 
therapy (Yang et al., 2019). The comparative stability of both free Ce6 and Ce6 
loaded nanobiocomposite under both physiological and intracellular pH 
conditions for 24 h was studied. The results are displayed in Figure 4.8 in pH 5.5, 
the stability free Ce6 was extensively reduced to 66.47 ± 4.53% in 2 h which 
continuously declined to 0.67 ± 2.2% at the end of the experiment, whereas the 
SWCNTs-HA-Ce6 was reduced to 88.43 ± 2.87 % in 2 h and showed 54.13 ± 
1.3% stable at the end of the experiment. In pH 7.4, the stability of free Ce6 was 
around 91.7 ± 0.63 % in 2 h and it was rapidly declined to 9.13 ± 5.34 % at the 






2 h and it considerably stable around 72.5 ± 2.89 % at the end of the experiment. 
These results suggested that the synthesized SWCNTs-HA-Ce6 was capable of 





Figure 4. 8 Stability studies of free Ce6 and SWCNTs-HA-Ce6 in two different pH 
conditions (pH 5.5 & 7.4). 
 
4.4. Ce6 Loading and In Vitro Ce6 Release Study  
The loading efficiency of Ce6 on SWCNTs-HA were calculated using UV-vis 






molecules. SWCNTs has large surface area, loading efficiency of Ce6 achieved 
at 70% calculated using the PS loading efficiency formulae mentioned in 3.3 
(Sundaram et al., 2020a). The results of in vitro Ce6 release studies in both 
intracellular (pH 5.5) and physiological (pH 7.4) conditions are shown in Figure 
4.9. The release behaviour of Ce6 was observed over a period of 4 days (96 
hours) at different time intervals. The results revealed that the Ce6 release 
behaviour in pH 5.5 was faster as compared to pH 7.4. The burst release of Ce6 
in pH 5.5 was observed around 33.8 ± 4.0 % for initial 6 h whereas it was only 
13.6 ± 0.69 % in pH 7.4. The slow and sustained release pattern of Ce6 from 
SWCNTs-HA-Ce6 was observed in the remaining hours. The release percentage 
of Ce6 was 76.8 ± 2.58 % in pH 5.5, whereas it was 34.8 ± 7.45 in pH 7.4 at the 
end of the experiment.  
 
Figure 4. 9 In vitro release of Ce6 from nanobiocomposite (SWCNTs-HA-Ce6) in 







To study the mechanism of release behaviour, the release study results from both 
pH 5.5 and 7.4 were substituted separately in different mathematical model 
equations and the obtained results are illustrated in Figure 4.10 and 4.11. In both 
pH 5.5 and 7.4 the higher R2 value was observed around 0.90855 and 0.90047 
respectively in Higuchi models than compared to other studied models. 
 
Figure 4. 10 Release kinetic profiles obtained for SWCNTs-HA-Ce6 in pH 5.5. [a] 
Zero order model, [b] First order model, [c] Higuchi model, and [d] Korsmeyer-
Peppas model. 
 
It indicates that the Ce6 release pattern from the SWCNTs-HA-Ce6 followed 
Higuchi kinetic release. In order to understand the mechanism of Ce6 release, 
we have applied the Korsmeyer-Peppas equation and the observed release 
exponent ‘n’ value was found to be 0.600 (in pH 5.5) and 0.742 (in pH 7.4). 






the different release mechanisms. If the ‘n’ value is 0.5, it indicate Fickian 
diffusion; if the ‘n’ value is in between 0.45<=0.89, it indicate Non-Fickian 
transport; if the ‘n’ value is 0.89, it indicate case II transport and the ‘n’ value is 
higher than 0.89, it indicate super case II transport (Gouda et al., 2017). In our 
study, the observed release exponent value of ‘n’ occurred between the range of 
>0.45 and <0.89 in both pH 5.5 and 7.4. It indicate that the Ce6 release 
mechanism was followed by Non-Fickian transport mechanism. Briefly, it was 
controlled by more than one process, it may be the coupling of fickian diffusion 
and polymer matrix relaxation (Chouhan et al., 2009). 
 
 
Figure 4. 11 Release kinetic profiles obtained for SWCNTs-HA-Ce6 in pH 7.4. [a] 







4.5. Intracellular Localisation of SWCNTs-HA-Ce6 on Colon Cancer Cell 
Lines 
Cellular localisation of synthesised SWCNTs-HA-Ce6 on Caco-2 cells were 
analysed using MitoTracker™ green FM and LysoTracker™ green, the 
autofluorescence of Ce6 and DAPI used as nuclei counter staining viewed under 
Zeiss Carl fluorescence microscope. Cellular localization was performed to 
investigate the cause and efficacy of SWCNTs-HA-Ce6 and their photo-induced 
cell death on colon cancer cell lines. The intensity of fluorescence was gradually 
increased based on the incubation time (Luo et al., 2015). The fluorescence 
intensity and distribution of SWCNTs-HA-Ce6 inside the Caco-2 cells were 




Figure 4. 12 Intracellular localisation of SWCNTs-HA-Ce6 using mito and 
lysotracker. Scale bar 50 µm. 
 
Cellular localisation of Ce6 was observed in red fluorescence, the nucleus was 
observed in blue fluorescence, and the mitochondrial and lysosome tracker were 
observed in green fluorescence. The results are shown in Figure 4.12 and the 






and distribution of Ce6 loaded nanobiocomposite was observed in the 
mitochondrial region compared to the lysosome region. The synthesized 
SWCNTs-HA-Ce6 were found within the intracellular region compared to 
extracellular region, and the Mito tracker staining revealed that the SWCNTs-HA-
Ce6 were predominantly localized at the mitochondrial region than lysosomes. 
Luo et al. 2015 have previously reported the similar cellular localization of Ce6. 
 
4.6. PDT Using SWCNTs-HA-Ce6 on Colon Cancer Cell Lines 
4.6.1. Morphology  
The qualitative and preliminary confirmation of cellular viability and cell death 
were analysed from cellular morphology using captured microscopic images. The 
IC50 concentration of SWCNTs-HA-Ce6 were 2.56 µg/mL and used it throughout 
this study (Sundaram et al, 2020a). The morphological observation of treated and 
untreated cells was captured using inverted light microscope for 0 h and 24 h and 
the images are shown in Figure 4.13. The close observation of Figure 4.13a 
revealed that there was a full confluence of cells at 0 and 24 h in controls and 
cells treated with SWCNTs, Ce6 and SWCNTs-HA-Ce6 at 0 J/cm2. In Figure 
4.13b and c revealed that there was a significant change in the cellular 
morphology of Caco-2 cells and pronounced more cell death was observed at 24 
h in the cells treated with SWCNTs, Ce6 and SWCNTs-HA-Ce6 at both 5 and 10 
J/cm2. It was previously reported that the morphological characteristics of the 
apoptotic cells were shown increased vacuoles, apoptotic structure, nuclear 






               
 
Figure 4. 13 Microscopic images of treated and untreated colon cancer cells. [a] 
untreated cells of 0 h and 24 h, [b] 0 h and 24 h of laser irradiated at 660 nm, 5 








4.6.2 Cytotoxicity analysis using Lactate dehydrogenase assay. 
The quantitative analysis of cell death was performed using LDH cytotoxicity 
assay kit. All the samples from 0, 5 and 10 J/cm2 at 24h were analysed to 
evaluate the cytotoxic behaviour of SWCNTs, Ce6 and SWCNTs-HA-Ce6. After 
the successful PDT treatment, the damaged cancer cell was released LDH 
enzyme into the cell culture media, and these media were analysed using LDH 
cytotoxicity assay kit. The measured absorbance value of untreated cells was 
kept as a control. Cytotoxicity assay results are shown in Figure 4.14, the 
observed results revealed that the non-irradiated 0 J/cm2 cells showed lower 
percentage of cytotoxic behaviour for SWCNTs 9%, Ce6 12% and SWCNTs-HA-
Ce6 18%. SWCNTs-HA-Ce6 treated cells showed the cytotoxicity of 84.9% at 10 
J/cm2 and 77% at 5 J/cm2. The results showed that the 10 J/cm2 treated cells had 
better cytotoxic behaviour compared to 5 J/cm2 laser treatment. In addition, the 
study revealed that the newly synthesised nanobiocomposite showed an 
improvement in cytotoxicity compared with free Ce6 treatment in both 5 J/cm2 
(63 %) and 10 J/cm2 (72.3%). 
This could be a result of the enhanced bioavailability and uptake profile of 
released Ce6 from nanobiocomposite, which led to the increased cytotoxic 
behaviour of SWCNTs-HA-Ce6 compared to free Ce6. The study also confirmed 
that the combined effect of laser irradiation (both 5 and 10 J/cm2) and 
nanobiocomposite treatment effectively inhibits the proliferation of Caco-2 cells. 
A comparison between 5 and 10 J/cm2 using the results of SWCNTs-HA-Ce6 
was performed at 24 h, and even though an increase in cytotoxicity was seen, 
there was no statistically significant difference was observed. Furthermore, we 
performed a comparison between Ce6 and SWCNTs-HA-Ce6 at both 5 and 10 
J/cm2 and these results showed that no significant differences were observed at 
5 J/cm2 (p = 0.118), but in 10 J/cm2 there was a significant increase in SWCNTs-






              
 
Figure 4. 14 The cytotoxicity effects of SWCNTs, Ce6, SWCNTs-HA-Ce6 on 
Caco-2 cells determined by LDH assay. Significance is shown as * p < 0.05; 
** p < 0.01; *** p 0.001. 
 
4.6.3 Cell death studies 
The cell apoptosis profile of laser irradiated cells was analysed using flow 
cytometry by FITC-Annexin V and PI staining method. The apoptotic inducing 
efficacy of nanobiocomposite after 24 h of PDT treatment was evaluated in this 
study. The percentage population of live cells (bottom left), early stage of 
apoptosis (bottom right), late stage of apoptosis (top right) and dead cells (top 
left) are represented in four different quadrant and the images are illustrated in 
Figure 4.15. The early and late stages apoptosis from treated groups were 







In early stage apoptotic cells, a statistical comparison between control and 
SWCNTs, Ce6 and SWCNTs-HA-Ce6 was performed. The 0 J/cm2 treated 
samples results showed that there was a significant difference observed in Ce6 
(p = 0.018) and SWCNTs-HA-Ce6 (p = 0.006), whereas there was no significant 
difference in SWCNTs (p = 0.175); the 5 J/cm2 treated samples results showed 
that there was a significant differences observed in SWCNTs (p = 0.029) and 
SWCNTs-HA-Ce6 (p = 0.022) whereas there was no significant differences in 
Ce6 (p = 0.291); and 10 J/cm2 treated samples results showed that there was no 
significant differences observed in SWCNTs (p = 0.432), Ce6 (p = 0.41) and 
SWCNTs-HA-Ce6 (p = 0.076).  
 
Similarly, a statistical comparison was performed between control and SWCNTs, 
Ce6 and SWCNTs-HA-Ce6 in late stage apoptotic cells and the 0 J/cm2 treated 
samples results showed that there was a significant differences observed in Ce6 
(p = 0.007) and SWCNTs-HA-Ce6 (p = 0.005), whereas there was no significant 
differences in SWCNTs (p = 0.207); the 5 J/cm2 treated samples results showed 
that there was a significant difference observed in SWCNTs-HA-Ce6 (p = 0.007), 
whereas there was no significant difference in SWCNTs (p = 0.164) and Ce6 (p 
= 0.201); and 10 J/cm2 treated samples results showed that there was a 
significant difference observed in Ce6 (p = 0.012), whereas there was no 







Figure 4. 15 Flow cytometry analysis using Annexin V PI for cell death, laser 
irradiated at 660 nm of fluence 0, 5 and 10 J/cm2 of SWCNTs, Ce6, SWCNTs-HA-








4.7 Isolation and Characterisation of Colon Cancer Stem Cells From 
Caco-2 Cell Lines. 
The colon cancer stem cells were isolated from Caco-2 colon cancer cell lines by 
magnetic bead isolation technique using CD133, CD44 and CD24 cell surface 
markers. It has been reported that CD133+, CD44+ and CD24+ markers from 
colon cancer cells were tumorigenic stem cells markers (Sahlberg et al., 2014). 
CSCs isolated from solid tumour have the potential to initiate tumour formation 
as well as differentiate and it has been demonstrated in the in vivo model (Chen 
et al., 2013). There are different studies explained the isolation and identification 
of CSCs using different markers, gene expression and cell signalling pathways 
(Kim et al., 2017; Jaggupilli et al., 2012). The most common method for isolating 
CSCs is to isolation side population cells based on the protein markers or cluster 
of differentiation markers, expressed on the outer surface of the cells (Khan et 
al., 2015). In this research study, isolation of side population from Caco-2 cells 
using MACs magnetic microbeads technique by CD133+, CD44+ and CD24+ 
markers. The characterization methods used to identify the isolated side 
population cells including CSCs spheroid morphology through microscopy, flow 
cytometry and immunofluorescence staining. 
4.7.1 Spheroid formation of isolated CCSCs 
Magnetic separated CCSCs were cultured using complete stem cell medium, the 
cultured cells able to self-renewal of stem cells and CSCs. The cultured cells 
grown very slow in ultra-low attachment flask. The morphology of the cells 
captured on day 1, day 2 and day 5 under inverted light microscope are shown 
in Figure 4.16. The images were confirmed the spheroid formation of isolated 
CCSCs using CD133, CD44 and CD24 markers. This result strongly suggested 
that isolated cells possess the characteristics of CSCs in colon cancer cell lines 
Caco-2. In this study, the isolated side population cells from Caco-2 cells were 
identified as colon cancer stem cells, which proliferated as mammospheres in in 
vitro model. The primary mammospheres could be enzymatically degraded into 







Figure 4. 16 Microscopic images of isolated CCSCs forming spheroid colonies 







4.7.2 Flow cytometry analysis 
The isolated CCSCs from different markers CD44+, CD133+ and CD24+ were 
analysed with BD Accuri C6 flow cytometry. The side population and non-side 
populations were stained using the following CD44-PE, CD133-FTIC and CD24-
Cy5 antigen antibody conjugation and the details are elaborately mentioned in 
section 3.9.2. Initially, the primary antibodies conjugated with fluorophore were 
mixed with the test samples by direct or indirect method before running the flow 
cytometry. In this experiment, the outlying cells and debris were excluded, and 
peaks were generated for 10,000 cells. Fluorescence detection using flow 
cytometry showed that the isolated cells expressed the markers CD133, CD44 
and CD24, the negative control comprising of the non-side population showed no 
fluorescence for all the three markers and the obtained results are given in Figure 
4.17. From colorectal cancer tumours isolated side populations are widely 
distributed with surface antigens CD133, CD44 and CD24 markers (Chu et al., 
2009; Sahlberg et al., 2014). 
The isolated cells express cell surface markers CD44 were tagged with 
phycoerythrin (PE) yellow orange region of visible spectrum and fluorescence 
detected using FL-2 with a 585/40 filter, 488 nm laser, PE maximum excitation at 
565 nm, emits at 573 nm. The results showed that CD 44 high expression about 
68.8 % in isolated CCSCs. CD 133 were tagged with FTIC shows green region 
of visible spectrum and fluorescence detected using FL-1 with a 533/30 filter, 488 
nm laser, FTIC maximum excitation at 494 nm, emits at 518 nm. CD 133 shows 
high expression on isolated CCSCs and the results showed about 53.2 %. 
CD 24 was tagged with Cy5 shows red region of visible spectrum and 
fluorescence detected using FL-3 with a 670 LP filter and 488 nm laser used. The 
maximum excitation of Cy5 at 650 nm and emits at 670 nm. CD 24 markers 
present on the isolated CCSCs were about 19.6%. The non-side population cells 
are tagged with CD44-PE, CD133-FTIC and CD24-Cy5 are analysed and the 
results showed no positive cells. Magnetic bead isolated cells are completely 
attracted the positive cells, and then the negative cells were collected in the 






cells were confirmed and combination of three markers distinguish that isolated 
CCSCs are more tumorigenic.  
 
Figure 4. 17 Expression of CD44, CD133 and CD24 surface markers as observed 







4.7.3 Immunofluorescence  
Immunofluorescence is a method to detect specific antigen antibody interactions 
to target antigen present within cell using fluorochrome attached antibodies 
visualised under fluorescence microscope. There are two types of 
immunofluorescence method: direct and indirect immunofluorescence. Direct 
method is a primary antibody linked with fluorophore to target specific antigen. 
Indirect method carried with two antibodies primary and secondary, whereas 
unlabelled primary antibody targets the antigen in the cell, then the fluorophore 
labelled secondary antibody recognise the primary antibody and binds to it 
(Mohan et al., 2008). In this study, we used both direct and indirect 
immunofluorescence. 
 
The isolated CCSCs were cultured using complete stem cell medium. The 
adherent culture of isolated CCSCs showed moderate expression of CD133, 
CD44 and CD24 markers for immunofluorescence were shown in Figure 4.18. 
CCSCs nuclei were counter stained using DAPI, and the markers CD133-FITC, 
CD44-PE and CD24-Cy5 by direct and indirect immunofluorescence technique 
mention in section 3.9.1.  CD133 markers are also called Promini-1 (PROM1), 
transmembrane glycoprotein mainly presents in plasma membrane and 
overexpressed in CSCs. Many studies reported that CD133 serve as 
independent marker for prognosis and chemoresistance in colon cancer (Ong et 
al., 2010; Coco et al., 2012). CD44 and CD24 markers have been widely used or 
putative markers to isolate CSCs (Slomianyl et al., 2009; Lee et al., 2010). 
Hyaluronan targeted CD44 receptors expressed on cancer cell surface and 
contributes to haemorrhage spreads when in contact with L- or P-selectins 
(Napier et al., 2007). Isolated CCSCs from Caco-2 cells showed the expression 
of all the three markers CD133, CD44 and CD24 clearly indicated in the presence 









Figure 4. 18 Fluorescent antigenic detection of the surface marker CD24, CD44 
and CD133 IFL staining of the isolated side population of CCSCs. DAPI nuclei 
counter staining. Scale bar 20 µm. 
 
4.8 Targeted Delivery of SWCNTs-HA-Ce6 on CCSCs 
The synthesised nanobiocomposite were coupled with HA to target the CD44 cell 
surface receptors, which is overexpressed in CCSCs. Isolated CCSCs, were 
cultured in petri dish with sterile glass slides and SWCNTs-HA-Ce6 were added, 
and SK-UT-1 cells were acted as a negative control for this study (CD44 receptor 
negative cells). The cells were incubated for 4 h at 37 °C in 5% CO2. The cellular 
imaging and targeting efficiency of SWCNTs-HA-Ce6 towards CD44 receptor 






Figure 4.19. Images were taken in all three channels (Mitotracker, DAPI and 
Ce6), and merged to study the targeting efficiency of SWCNTs-HA-Ce6. 
 
Figure 4. 19 Targeted delivery of SWCNTs-HA-Ce6. [a] Isolated CCSCs (CD44 
receptor positive cells) and [b] SK-UT-1 cells (CD44 receptor negative cells). Scale 







In contrast, the study performed in CCSCs (Figure 4.17a) showed the 
fluorescence intensity and cellular uptake of Ce6 in the SWCNTs-HA-Ce6 
channel. It is further concluded that the HA functionalized SWCNTs-HA-Ce6 
facilitates the targeting ability for SWCNTs-HA-Ce6 onto CD44 positive cells. The 
close observation of the Figure 4.19a revealed that the presence of SWCNTs-
HA-Ce6 fluorescence intensity in the mitochondrial region. The results are clearly 
demonstrated that there is no prominent update of SWCNTs-HA-Ce6 in SK-UT-
1 cells due to the absence of CD44 cell surface receptor (Figure 4.19b).  Mainly 
the SWCNTs-HA-Ce6 molecule located in the mitochondrial region CCSCs, 
which leads to destroy the spheroid or clump of cells by laser radiation (Liu et al., 
2014). It is further concluded that the HA functionalized SWCNTs-HA-Ce6 
facilitates the targeting ability for SWCNTs-HA-Ce6 onto CD44 positive cells. 
From this study, the synthesised SWCNTs-HA-Ce6 could be used as a potential 
targeting nanomaterial to target CCSCs in cancer therapy.   
 
4.9 Photodynamic Therapy Effect on Isolated CCSCs Using SWCNTs-
HA-Ce6 
4.9.1 Cell morphology study 
Isolated CCSCs from Caco-2 cells were cultured on petri dishes at the population 
of 4 × 105 cells and the cells were further treated with laser irradiation at 660 nm 
fluence of 5 and 10 J/cm2 after reaching the confluency. The morphological 
observation of treated and untreated cells was captured using inverted light 
microscope for 0 h, 24 h and 48 h and the images are shown in Figure 4.20, 4.21 
and 4.22. The qualitative and preliminary confirmation of cellular viability and cell 
death were analysed from cellular morphology using captured microscopic 
images. The SWCNTs-HA-Ce6 treated and laser-irradiated (5 J/cm2) cells 
revealed that significant changes in the cellular morphology at 48 h (Figure 4.21) 
compared to the control images. Similarly, the SWCNTs-HA-Ce6 treated and 
laser-irradiated (10 J/cm2) cells morphology revealed that severe morphological 
changes and pronounced more cell death was observed at 48 h and the images 









Figure 4. 20 Morphology analysis using microscopic images of treated and 








Figure 4. 21 Morphology analysis using microscopic images of treated and 








Figure 4. 22 Morphology analysis using microscopic images of treated and 
untreated CCSCs at 0 h, 24 h and 48 h of laser irradiated at 660 nm, 10 J/cm2. 
 
4.9.2 Cell death studies 
4.9.2.1 LDH cytotoxicity assay 
The cytotoxicity behaviour of SWCNTs-Ce6-HA was analysed using LDH 
cytotoxicity assay kit. The isolated CCSCs were incubated with Ce6 and 
SWCNTs-Ce6-HA, and then irradiated at 660 nm of laser fluence 0, 5 and 10 
J/cm2 at 24 and 48 h. After the successful PDT treatment, the damaged cancer 






analysed using LDH cytotoxicity assay kit.  The measured absorbance value of 
untreated cells was kept as a control.  The assay results are shown in the Figure 
4.23 & 4.24. 
 
 
Figure 4. 23 The cytotoxicity effects of Ce6, SWCNTs-HA-Ce6 on CCSCs, laser 
irradiated at 660 nm of fluence 0, 5 and 10 J/cm2 incubated for 24 h and determined 
cytotoxicity by LDH assay. significance is shown as * p < 0.05; ** p < 0.01; *** p 
0.001. 
The 24 h cytotoxicity assay results are shown in Figure 4.23, the observed results 
revealed that the non-irradiated 0 J/cm2 showed lower percentage of cytotoxic 
behaviour for Ce6 (27.25 %) and SWCNTs-HA-Ce6 (35.94 %). The results of 






showed the cytotoxicity of 56.3% whereas the percentage cytotoxicity for Ce6 
was 48.9 %. The results of laser irradiation at 10 J/cm2, revealed that the 
SWCNTs-HA-Ce6 treated cells showed the cytotoxicity of 74.8% whereas the 
percentage cytotoxicity for Ce6 was 60.8 %. At 24 h, the percentage of 
cytotoxicity was significantly increased in 10 J/cm2 irradiated and SWCNTs-HA-
Ce6 treated samples compared to 5 J/cm2 (p < 0.05) and 0 J/cm2 (p < 0.01). The 
percentage of cytotoxicity was significantly increased in 10 J/cm2 irradiated and 
Ce6 treated samples compared to 0 J/cm2 (p < 0.001), similarly the cytotoxicity 
was significantly increased in 5 J/cm2 irradiated and Ce6 treated samples 
compared to 0 J/cm2 (p < 0.01). There was no statistical significant differences 
were observed in 0 J/cm2 irradiated and SWCNTs-HA-Ce6 treated samples 
compared to 5 J/cm2 (p = 0.059); 5 J/cm2 irradiated and Ce6 treated samples 
compared to 10 J/cm2 (p = 0.051). 
The 48 h cytotoxicity assay results are shown in Figure 4.24, the observed results 
revealed that the non-irradiated 0 J/cm2 showed lower percentage of cytotoxic 
behaviour for Ce6 (32.79%) and SWCNTs-HA-Ce6 (35.59%). The results of laser 
irradiation at 5 J/cm2, revealed that the SWCNTs-HA-Ce6 treated cells showed 
the cytotoxicity of 71.85% whereas the percentage cytotoxicity for Ce6 was 
60.9%. The results of laser irradiation at 10 J/cm2, revealed that the SWCNTs-
HA-Ce6 treated cells showed the cytotoxicity of 86.7% whereas the percentage 
cytotoxicity for Ce6 was 67.7%. At 48 h, the percentage of cytotoxicity was 
significantly increased in 10 J/cm2 irradiated and SWCNTs-HA-Ce6 treated 
samples compared to 0 J/cm2 (p < 0.01), similarly the cytotoxicity was 
significantly increased in 5 J/cm2 irradiated and SWCNTs-HA-Ce6 treated 
samples compared to 0 J/cm2 (p < 0.01). The percentage of cytotoxicity was 
significantly increased in 10 J/cm2 irradiated and Ce6 treated samples compared 
to 0 J/cm2 (p < 0.05). There was no statistical significant differences were 
observed in 0 J/cm2 irradiated and SWCNTs-HA-Ce6 treated samples compared 
to 5 J/cm2 (p = 0.084); 5 J/cm2 irradiated and Ce6 treated samples compared to 
10 J/cm2 (p = 0.476); and 5 J/cm2 irradiated and SWCNTs-HA-Ce6 treated 
samples compared to 10 J/cm2 (p = 0.117). 
The percentage of cytotoxicity results are considered as important parameter for 






cytotoxicity during 48h at 10 J/cm2 results indirectly revealed the enhanced 
bioavailability, uptake profile and biological activity of Ce6 released from 
SWCNTs-HA-Ce6. The percentage of cytotoxicity results also revealed that the 
increased cytotoxic effects of SWCNTs-HA-Ce6 compared with Ce6 alone in 5 
and 10 J/cm2 at both 24 and 48 h. 
 
Figure 4. 24 The cytotoxicity effects of Ce6, SWCNTs-HA-Ce6 on CCSCs, laser 
irradiated at 660 nm of fluence 0, 5 and 10 J/cm2 incubated for 48 h and determined 








4.9.2.2 Annexin V–fluorescein isothiocyanate (FITC) and Propidium 
Iodide (PI) assay using flow cytometry 
The cell death mechanism of PDT was well established that directly destroy the 
cancer cells by apoptosis or necrosis (Yoo et al., 2012). Photodynamic effects 
induce the cell death by formation of ROS damage the cells by oxidizing and 
degrading cellular components. To estimate the cell death mechanism study of 
PDT in isolated CCSCs, an Annexin V PI cell death assay by flow cytometry. The 
CCSCs were cultured in small petri dishes and incubated with Ce6 and SWCNTs-
Ce6-HA, then treated with 0, 5 and 10 J/cm2 at 660 nm. After treatment the cells 
were incubated for 24 and 48 h and evaluated in this study. Flow cytometry 
analysis pattern as discussed early; four quadrant images are given in Figure 
4.25 and 4.26. The percentage of early and late stages apoptosis cells from 
treated groups are comparatively higher than control cells. The percentage of 
cells in the early and late apoptosis quadrant will leads to cell death. 
 
At 24 h (Figure 4.25), the SWCNTs-HA-Ce6 treated cells with no laser irradiation 
(0 J/cm2) showed that the percentage of EA and LA about 12.8 and 2.9 % 
whereas the Ce6 treated EA and LA about 1.4 and 4.3 %. The SWCNTs-HA-Ce6 
treated cells with the 5 J/cm2 laser fluence showed that the percentage of EA and 
LA about 12.7 and 2.6 % whereas the Ce6 treated EA and LA about 10.5 and 2.0 
%. The SWCNTs-HA-Ce6 treated cells with 10 J/cm2 laser fluence showed that 
the percentage of EA and LA about 20.2 and 2.7 % whereas the Ce6 treated EA 
and LA about 16.9 and 4.2 %. %. The Ce6 treated samples showed lesser 
percentage of EA and LA cells in 0, 5 and 10 J/cm2 irradiated samples compared 
to SWCNTs-HA-Ce6. The results of SWCNTs-HA-Ce6 treated and 10 J/cm2 
irradiated samples showed the prominent apoptotic effects to the CCSCs 







Figure 4. 25 Flow cytometry analysis using Annexin V PI for cell death, laser 
irradiated at 660 nm of fluence 0, 5 and 10 J/cm2 of Ce6, SWCNTs-HA-Ce6 on 








Figure 4. 26 Flow cytometry analysis using Annexin V PI for cell death, laser 
irradiated at 660 nm of fluence 0, 5 and 10 J/cm2 of Ce6, SWCNTs-HA-Ce6 on 







At 48 h (Figure 4.26), the SWCNTs-HA-Ce6 treated cells with no laser irradiation 
(0 J/cm2) showed that the percentage of EA and LA about 13.6 and 2.4 % 
whereas the Ce6 treated EA and LA about 12.9 and 1.7 %. The SWCNTs-HA-
Ce6 treated cells with the 5 J/cm2 laser fluence showed that the percentage of 
EA and LA about 45.7 and 2.6 % whereas the Ce6 treated EA and LA about 36.2 
and 2.9%. The SWCNTs-HA-Ce6 treated cells with 10 J/cm2 laser fluence 
showed that the percentage of EA and LA about 50.5 and 2.8 % whereas the 
Ce6 treated EA and LA about 40.4 and 2.5 %. The Ce6 treated samples showed 
lesser percentage of EA and LA cells in 0, 5 and 10 J/cm2 irradiated samples 
compared to SWCNTs-HA-Ce6. The results of SWCNTs-HA-Ce6 treated and 10 
J/cm2 irradiated samples showed the prominent apoptotic effects to the CCSCs 
compared to the control. 
 
4.9.3 Metabolic activity of Cells using Adenosine Triphosphate (ATP) 
luminescence assay 
Adenosine triphosphate are the energy source of cell metabolism and 
proliferation. Cancer cells produce more number of ATPs through aerobic 
glycosylation for continuous division of cells (Vander Heiden et al., 2009). The 
metabolic activity of the isolated CCSCs was analysed by measuring the ATP 
luminescence signal before and after the treatment. CCSCs were cultured and 
treated with Ce6 and SWCNTs-HA-Ce6 at 660 nm of fluence 5 and 10 J/cm2, 
amount of ATP production was estimated at 24 and 48 h. Control cells showed 
higher production of ATP and it was confirmed by the luminescent RLU obtained 
through this study. The metabolic activity of cells slowly declined at 5 and 10 
J/cm2 laser irradiated and SWCNTs-HA-Ce6 treated samples and the calculated 
by ATP production rate using luminescent RLU are given in Figure 4.27 and 4.28. 
 
The 24 h ATP luminescence assay results are shown in Figure 4.27, the 
observed results revealed that the non-irradiated 0 J/cm2 and SWCNTs-HA-Ce6 
treated samples showed higher luminescence compared to 5 J/cm2 and 10 J/cm2. 
It indicates the number of viable cell counts were gradually decreased in both to 
5 J/cm2 and 10 J/cm2. The luminescence signal was significantly decreased in 






(p < 0.001) and 0 J/cm2 (p < 0.001), similarly the luminescence signal was 
significantly decreased in 10 J/cm2 irradiated and Ce6 treated samples compared 
to 5 J/cm2 (p < 0.001) and 0 J/cm2 (p < 0.001). The results of 5 J/cm2 irradiated 
and Ce6 treated samples compared to 0 J/cm2 (p < 0.05) and the 5 J/cm2 




Figure 4. 27 An ATP luminescent assay of Ce6, SWCNTs-HA-Ce6 on CCSCs, laser 
irradiated at 660 nm of fluence 0, 5 and 10 J/cm2 incubated for 24 h. Significance 









Figure 4. 28 An ATP luminescent assay of Ce6, SWCNTs-HA-Ce6 on CCSCs, laser 
irradiated at 660 nm of fluence 0, 5 and 10 J/cm2 incubated for 24 h. Significance 
is shown as *** p 0.001. 
 
The 48 h ATP luminescence assay results are shown in Figure 4.28, the 
observed results revealed that the non-irradiated 0 J/cm2 and SWCNTs-HA-Ce6 
treated samples showed higher luminescence compared to 5 J/cm2 and 10 J/cm2. 
It indicates the number of viable cell counts were gradually decreased in both to 
5 J/cm2 and 10 J/cm2. The luminescence signal was significantly decreased in 
10 J/cm2 irradiated and SWCNTs-HA-Ce6 treated samples compared to 5 J/cm2 
(p < 0.001) and 0 J/cm2 (p < 0.001), similarly the luminescence signal was 
significantly decreased in 10 J/cm2 irradiated and Ce6 treated samples compared 
to 5 J/cm2 (p < 0.001) and 0 J/cm2 (p < 0.001). The results of 5 J/cm2 irradiated 






irradiated and SWCNTs-HA-Ce6 treated samples compared to 0 J/cm2 (p < 
0.001). 
The metabolic activity of CSCs or SCs have decreased or quiescent, ultimately 
effects the growth of tumour or metastasis in the affected region (Peiris-pages et 
al., 2016). The results showed that RLU value of 5 and 10 J/cm2 are lower 
compared with 0 J/cm2 in both 24 and 48 h, without treatment the proliferation 
rate of cells was high. These results demonstrate that the SWCNTs-HA-Ce6 
treated samples were showed lower metabolic rate or ATP production in the cells 
and it directly leads to inactive and cell death. 
 
4.10 Nuclear Damage Studies Using Hoechst And Propidium Iodide 
CCSCs were cultured in sterile glass coverslip and incubated with Ce6 and 
SWCNTs-HA-Ce6 and then laser irradiated at 660 nm in fluence 5 and 10 J/cm2. 
The morphological changes in the nucleus were captured under fluorescent 
microscope, here Hoechst stain represented in blue colour and PI represented in 
red colour. Hoechst is a nucleic acid dye, it will permeable into the cells and 
nucleus to recognise chromatin condensation and fragmentation, this staining 
used to identify condensed nuclei of apoptotic cells. PI is a cell impairment DNA-
binding dye used as counter stain for Hoechst, PI will stain the cells only where 
there is increase in plasma membrane permeability and enters the nucleus 
(Ahmed Hamdi et al., 2014).  
The morphological observation of 0, 5 and 10 J/cm2 laser irradiation and Hoechst 
PI staining were shown in figure 4.29. As observed in control image, the cells are 
seen oval nucleus and less bright blue fluorescence stained with Hoechst and no 
trace of red fluorescence of PI dye. The PDT treated cells exhibited features of 
apoptosis such as chromatin condensation, fragmentation, and cell shrinkage. 
The images of 5 J/cm2 showed that bright blue fluorescence of Hoechst and less 
red fluorescence of PI dye, the nucleus shapes were changed. In the 10 J/cm2 
treated cell nucleus were completely damaged and irregular in shapes, and then 
the bright red fluorescence of PI dye and very less fluorescence of Hoechst stain 
in the nucleus area were observed. This result shows that nuclear damage of 
CCSCs were occurred during PDT treatment, there is high damage in 10 J/cm2 







Figure 4. 29 Nuclear damage analysis of CCSCs after laser irradiation at 660 nm of 
fluence 0, 5 and 10 J/cm2 of Ce6, SWCNTs-HA-Ce6 using Hoechst and PI. Scale 
bar 50 µm. 
 
4.11 Oxidative Stress Visualisation Immediately Following Laser 
Irradiation. 
Level of ROS production is important criteria in laser irradiation, PDT mechanism 
are type I and type II, both mechanisms based of the production of ROS leads to 
cellular damage or cell death. The fluorescence microscopy experiment was 






irradiated CCSCs. CCSCs were cultured on glass cover slip containing petri 
dishes and treated with SWCNTs-HA-Ce6 at 0, 5 and 10 J/cm2 fluence.  
 
Figure 4. 30 Detection of oxidative stress on CCSCs using intracellular ROS kit. 
CCSCs are laser irradiation at 660 nm of fluence 0, 5 and 10 J/cm2 of Ce6, SWCNTs-
HA-Ce6 and fluorescence intensity of the merged images are represented in 







After one hour of incubation fluorometric intracellular reactive oxygen species kit 
was used to analysis the production of ROS in the CCSCs and visualised under 
fluorescent microscope and DAPI used as nuclei counter staining. The captured 
images are represented in figure 4.30, the results showed that 0 J/cm2 did not 
produced any red fluorescence due to the absence of ROS production. Laser 
irradiated 5 J/cm2 and 10 J/cm2 fluence showed the presence of red fluorescence 
in different ranges and it can be measured and represented as fluorescence 
intensity. 5 J/cm2 showed less ROS production compared with 10 J/cm2, the ROS 





























CHAPTER 5                              CONCLUSION 
 
The use of SWCNTs-based materials showed great benefits in the preparation 
of nanoengineered vehicles for drug delivery and biomedical application. This 
study aimed to use the functional applications of SWCNTs, hyaluronic acid and 
Chlorin e6 as a combined targeted delivery vehicle called “Nanobiocomposite 
(SWCNTs-HA-Ce6)” and utilizing their photodynamic effects by irradiating at 660 
nm. To conclude, SWCNTs coupled biopolymer HA and coated with Ce6 were 
successfully synthesised which showed photodynamic effect under 660 nm to 
treat colon cancer cells and CCSCs.  
The physicochemical characterisation of synthesised SWCNTs-HA-Ce6 showed 
the existence of HA and Ce6. The nanocarrier properties of synthesized 
SWCNTs-HA-Ce6 was confirmed through  the presence of functional group bond 
shifting in FTIR study, surface charge of the nanotubes in DLS method, size and 
shape of the SWCNTs-HA-Ce6 in HRTEM study, and crystallinity and purity of 
the SWCNTs-HA-Ce6 in XRD. The dispersibility of the SWCNTs-HA-Ce6 were 
considerably improved when compared with void SWCNTs. It may due to the 
surface functionalisation of SWCNTs with hyaluronic acid. 
The SWCNTs-based nanomaterials showed an improved loading efficiency, 
stability and sustained release of photosensitizers and these parameters are 
considered as an important criterion in photodynamic therapy. It plays major role 
in drug and dosage formulations in PDT related clinical trials for the treatment of 
cancer. An improved stability of nanobiocomposite was obtained in both 
physiological pH 7.4 and intracellular pH 5.5. SWCNTs-HA-Ce6 was capable of 
protecting the stability of loaded Ce6. The in vitro release study results revealed 
the slow and sustained release pattern of Ce6 from SWCNTs in both pH 
conditions. Ce6 release was significantly faster in pH 7.4 than compared to pH 
5.5.  
The synthesized nanobiocomposite was successfully studied using both colon 
cancer cells and CCSCs in in vitro. It shows positive outcomes in targeting 
CCSCs and pronounced cell death. Performance of PDT depends primarily on 
the release of singlet oxygen, absorbed light and their cellular penetration depth, 






effects of SWCNTs-HA-Ce6 were studied in Caco-2 cells and it showed 
significant cytotoxicity effect in the laser fluence of 10 J/cm2 at 24 h compared to 
void Ce6 and SWCNTs. There was no significant cytotoxicity for SWCNTs at 660 
nm because the maximum excitation of SWCNTs were at 808 nm under laser 
irradiation.  
Recently, CSCs have been identified in various solid tumours and have been 
proposed to explain the radiotherapy and metastatic potential, recurrence, and 
resistance to chemotherapy caused by certain tumours. Many studies suggested 
that solid tumours contain small population of cells that can self-renew, proliferate 
infrequently initiate and metastasis the tumours (Chang et al., 2016). In cancer 
therapy, the current treatments methodologies are prone to destroy only tumour 
cells and sometimes it fails to target and eradicate CSCs; therefore, new 
therapies are needed to target and destroy CSCs and to completely eradicate 
the tumour. In our research, CCSCs were successfully isolated from colon cancer 
cell line (Caco-2), and then the presence of isolated CCSCs were confirmed by 
different characterisation techniques which includes using immunofluorescence, 
flow cytometry and CCSCs spheroid morphology formation in microscopy. 
Cellular localisation of SWCNTs-HA-Ce6 on Caco-2 cells and CCSCs were 
studied in fluorescence microscopy and it revealed that the Ce6 fluorescence 
signals were clearly seen in the mitochondrial region, so that SWCNTs-HA-Ce6 
capable of damaging the powerhouse of the cell.  
The synthesised SWCNTs-HA-Ce6 successfully targeted the CCSCs and 
release the Ce6 molecule to destroy the CCSCs. CCSCs are overexpressed with 
cells surface markers like CD133, EpCAM, CD24, CD44, and the functionalised 
HA on SWCNTs are targeting the CD44 receptors. CCSCs are irradiated at 660 
nm in two different laser fluence (5 and 10 J/cm2) for 24 and 48 h and studied 
various parameters to confirm the efficacy of SWCNTs-HA-Ce6. The better 
cytotoxic behaviour was observed on the CCSCs were irradiated with 10 J/cm2 
compared to 5 J/cm2. The cells treated with 10 J/cm2 indicated higher percentage 
of cell death, higher apoptotic activity and prominent nuclear damage inside the 
cells compared to 5 J/cm2. Through the present study, a novel SWCNTs-HA-Ce6 






CCSCs. Overall, these results showed that the synthesized SWCNTs-HA-Ce6 




Future studies should be identifying the in vitro molecular pathways, which leads 
to the cell death in CCSCs, and then the similar in vitro approaches of SWCNTs-
HA-Ce6 should be tested in in vivo mice model. These findings should be studied 
to find out the pharmacokinetic and pharmacodynamics effects of SWCNTs-HA-
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B1: List of consumables  
 
Product Catalogue number Company/supplier 
35mm x 10mm Style 
Treated Polystyrene Cell 
Culture Dish 
430165 Corning incorporated 
10 mL Disposable pipette BD357551 Beckson Dickinson 
10 mL stripette serological 
pipets  
4488 Corning incorporated 
5 mL disposable pipette BD357543 Beckson Dickinson 
5 mL stripette serological 
pipets  
4051 Corning incorporated 
Centrifuge tubes, 50 mL, 
PP flat top, sterile, bulk 
CR430489 Corning incorporated 
Eppendorf®, Microtubes Z666521 Sigma Aldrich 
Eppendorf®, Microtubes Z666505 Sigma Aldrich 
Eppendorf®, Microtubes Z666515 Sigma Aldrich 
Microplate, 96 well, F-





Microplate, 96 well, F-
Bottom (Chimney well), 
white, lumitrac, high 





Microscope slides, frosted 










Thermo Fisher Scientific 
Falcon (5mL) Polystyrene 




























































B2: List of equipment’s 
 









50129688 Thermo Scientific™ 
 
Biological Safety Cabinet  Airvolution 
-80 ºC Freezer 
United Scientific  






















X1 Centrifuge Series 
 
75004250 Thermo Scientific™ 
 
Heraeus™ Fresco™ 17 
Microcentrifuge 
 







Heracell™ 150i CO2 
Incubator 



















660 nm laser  National Laser Centre, 
South Africa 







Spectrum 100 PerkinElmer 
 





C6 flow cytometer 
 
BD ACCURI C6 PLUS BD Biosciences 
 






JEM 2100F  200 kV FE JEOL Ltd 
X-ray diffractometer  Ultima lV Rigaku  
Zeta sizer  ver. 7.10 Malvern Instruments Ltd 
Magnetic stirrer RCT basic IKA 
-80 ºC Freezer 
 




B3: List of reagents and media 
 
Product Catalogue number Company/supplier 
Single walled carbon 
nanotubes 
652490 Sigma-Aldrich 







Hyaluronic acid 40583 Sigma-Aldrich 
Nitric acid 438073 Sigma-Aldrich 
Membrane filter pore size 
0.22 µm 
S2GPU05RE Merck 




N-hydroxysuccinimide 130672 Sigma-Aldrich 
Triethylamine 99 % T0886 Sigma-Aldrich 
Dialysis bag D9777 Sigma-Aldrich 
Tween80 P1754 Sigma-Aldrich 
Caco-2 cell lines HTB-37™ ATCC® 
 










 51412C Sigma-Aldrich 
foetal bovine serum F9665 Sigma-Aldrich 
L-glutamate G7513 Sigma-Aldrich 








CD133 microbead kit 130-050-801 Miltenyi Biotec 
CD44 microbead kit 130-095-194 Miltenyi Biotec 
CD24 microbead kit 130-095-951 Miltenyi Biotec 




Anti-human CD133 ZRB 1013, human/rabbit, 
clone F8, ZooAb 
Merck 
Anti-human CD24 555426, human/mouse, 
clone ML5 
BD Biosciences 
FTIC Mouse anti-rabbit 
antibodies 







Cy5 goat anti mouse 
antibodies 
NB7602 Novus Bio, 









Ethanol Absolute 99.9% 
 
IS-O 9001 Glassworld 
 
FITC Annexin V 
Apoptosis Detection Kit I 
 
556547 BD Pharmingen™ 
 
Flow Cytometer Fluid Kit 
 











MitoTracker™ Green FM 1890551 Invitrogen™ 
 
































































C1. Calculation of cell amount and viability 
The percentage viability and number of cells per mil were retrieved using the 
Countess™ II Automated Cell Counter. From the results obtained Total amount 
of cells in suspension was calculated as follows: 
𝑇𝑜𝑡𝑎𝑙 𝑐𝑒𝑙𝑙𝑠 𝑝𝑒𝑟 𝑚𝑙×𝑆𝑢𝑠𝑝𝑒𝑛𝑠𝑖𝑜𝑛 𝑣𝑜𝑙𝑢𝑚𝑒(𝑚𝑙)=𝑇𝑜𝑡𝑎𝑙 𝑎𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠 𝑖𝑛 𝑠𝑢𝑠𝑝𝑒𝑛𝑠𝑖𝑜𝑛 
C2. Calculation of volume of cell seeding density in a cell culture flask 
Cryopreserved cells are cultured from liquid nitrogen. One ampule will be culture 
in a 25 cm2 T-flask in 5 mL complete culture media. Cells are incubated and 
allowed to grow until confluency. Cells are passaged once confluent into a larger 
TC flask i.e. 75 cm2 with complete growth media of 15 mL. Cells are detached 
and counted (C1). The proposed number of cells for a 75 cm2 flask is 2 × 106. 
The volume of cells to be seeded from the cell suspension is as follows: 
𝑇𝑜𝑡𝑎𝑙 𝑎𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠 𝑖𝑛 𝑠𝑢𝑠𝑝𝑒𝑛𝑠𝑖𝑜𝑛
= 𝑇𝑜𝑡𝑎𝑙 𝑐𝑒𝑙𝑙𝑠 𝑝𝑒𝑟 𝑚𝐿 × 𝑆𝑢𝑠𝑝𝑒𝑛𝑠𝑖𝑜𝑛 𝑣𝑜𝑙𝑢𝑚𝑒(𝑚𝐿) 
𝐶𝑒𝑙𝑙 𝑠𝑒𝑒𝑑𝑖𝑛𝑔 =




C3. Calculation for cell seeding density of 3.4 cm petri dishes 
The cell seeding density for culturing cells in a 3.4 cm petri dish is cell line 
dependant. An optimum seeding density is predetermined in order to carry out 
downstream biochemical applications. The optimum seeding density for Caco-2 
colon cancer is at 5 × 105 cells in 3 mL media. The volume of cells to seed from a 
suspension is as follows: 
𝑇𝑜𝑡𝑎𝑙 𝑎𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠 𝑖𝑛 𝑠𝑢𝑠𝑝𝑒𝑛𝑠𝑖𝑜𝑛
= 𝑇𝑜𝑡𝑎𝑙 𝑐𝑒𝑙𝑙𝑠 𝑝𝑒𝑟 𝑚𝐿 × 𝑆𝑢𝑠𝑝𝑒𝑛𝑠𝑖𝑜𝑛 𝑣𝑜𝑙𝑢𝑚𝑒(𝑚𝐿) 
𝐶𝑒𝑙𝑙 𝑠𝑒𝑒𝑑𝑖𝑛𝑔 =








C4. Calculation for average laser irradiation times 
The laser power output was measured using a Laser Power Meter and used to 
calculate the time of laser exposure according to the energy that is given. Laser 



















C5. Calculation for PS loading efficiency  
The loading efficiency of PS on SWCNTs were calculated using the below formula: 
𝑃𝐿𝐸 ( %) =
𝑤𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑙𝑜𝑎𝑑𝑒𝑑 𝑃𝑆 
𝑤𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑃𝑆 𝑖𝑛𝑓𝑒𝑒𝑑
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